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ABSTRACT

Caspase-3 is a cysteine protease that hydrolyzes diverse intracellular proteins during
programmed cell death (known as apoptosis). It has been a popular target for drug design against
abnormal cell death for more than a decade. No approved caspase based drug, however, is
available so far. Therefore, structural insights about the substrate recognition of caspase-3 are
needed for the future development of caspase-3 based inhibitors and drugs. In this study, crystal
structures of recombinant caspase-3 in complex with seven substrate analog inhibitors, including
acetyl (Ac)-DEVD-aldehyde (Cho), Ac-DMQD-Cho, Ac-IEPD-Cho, Ac-YVAD-Cho, AcWEHD-Cho, Ac-VDVAD-Cho, and tert-butoxycarbonyl (Boc)-D-fluoromethylketone (Fmk),
have been analyzed in combination with enzyme kinetic data and computational models.
Seven crystal structures were determined at resolutions of 1.7-2.6Å. The binding
conformation of each inhibitor residue at P1-P4 position was analyzed. The negative P1 aspartic
acid side chain is exclusively required by the positive S1 pocket of caspase-3. Small hydrophobic
P2 residues are preferred by the nonpolar S2 pocket formed by Y204, W206, and F256.

Although hydrophilic residues at P3 position tend to fit better, hydrophobic residues also can be
accommodated by the plastic S3 pocket. Two substrate binding sites were found in the S4 pocket,
one formed by main chain atoms of F250 and side chain atoms of N208 and the other formed by
aromatic side chains of W206 and W214. These two binding sites are responsible for the binding
of hydrophilic and hydrophobic P4 residues, respectively. Furthermore, the S5 subsite of
caspase-3 formed by side chains of F250 and F252 was discovered. It stabilizes hydrophobic P5
residues on the substrates by an induced fit mechanism.
Computational studies were performed to help improve prediction of protein structures
and protein-ligand interactions. Based on the Morse’s function, a novel potential function with
only three adjustable parameters per residue pair was developed, which will significantly
increase the efficiency of protein structure prediction and molecular mechanics. Altogether, our
studies have provided valuable information for the future caspase-3 based drug development.

INDEX WORDS: Enzyme catalysis, Cysteine protease, Protein recognition, Apoptosis,
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1. GENERAL INTRODUCTION
1.1. Caspase Enzyme
Caspases are cysteinyl aspartate proteases that specifically cleave their substrate proteins
after an aspartic acid. Since the discovery of the first caspase family member caspase-1 ( initially
known as interleukin-1b-converting enzyme, ICE) in 1992 (Cerretti, Kozlosky et al. 1992;
Thornberry, Bull et al. 1992), numerous caspase family members have been found in various
vertebrate and invertebrate species, including 11 in humans, 10 in mice, 4 in birds, 4 in zebra fish,
8 in amphibians, 7 in insects, and 3 in nematodes (Lamkanfi, Declercq et al. 2002). Caspases are
widely involved in differentiation, cell death, and inflammation processes. Although many
caspases function in nonapoptotic pathways, the evolutionarily conserved role of caspases is to
execute programmed cell death.
Caspase zymogens (known as procaspases) consist of three domains. A big subunit with a
molecular weight around 20 kDa (p20) and a small subunit around 10 kDa (p10) are connected
by a short linker region. At the N-termini, different caspases have their prodomains varying in
length (figure 1.1). Some of them have big prodomains, such as caspase-2, 8, and 9. These
caspases usually interact with death-inducing signaling complex (DISC) through their
prodomains during the activation process. Other caspases, such as caspase-3, 6, and 7, have short
prodomains, and their activation normally depends on cleavage by other caspases. The full
length sequences of human caspases share homologies from 20% to 77%. Caspase-4 and 8 share
the lowest homology while caspase-4 and 5 share the highest (Cohen 1997).
Procaspases have limited catalytic activities. During maturation, the prodomain is
removed and the linker region between p20 and p10 is cleaved. As a result, two subunits will be
assembled into a heterodimer p10/p20 which contains one catalytic groove responsible for
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substrate recognition and hydrolysis. X-ray crystallography data suggested that caspases
normally form heterotetramers (p10/p20)2 under physiological conditions, although it is not
required for the catalytic activity.
Based on their physiological functions in cells, caspases are divided into inflammatory
caspases and apoptotic caspases. As illustrated in the Figure 1.1, the group I caspases, including
caspase-1, 4, 5, 11, 12, 13, 14, belong to inflammatory caspases. Apoptotic caspases fall into two
subgroups based on the position and function in the apoptotic signaling pathways. Caspase-2, 8,
9, 10 are initiator caspases (group II) and caspase-3, 6, 7 are executioner caspases (group III).
The detailed functions of apoptotic caspases are introduced in the following section.
1.2. Caspases and Apoptosis
The programmed cell death, also named apoptosis, is a critical event in the cell life cycle.
It is characterized by a series of highly ordered cell morphological and biochemical changes,
including blebbing, loss of membrane asymmetry and attachment, cell shrinkage, nuclear
fragmentation, chromatin condensation, and chromosomal DNA fragmentation. In the end, the
cell will be lysed and debris will be degraded. In general, apoptosis occurs when a cell is injured
beyond repair, infected by virus, or under stressful conditions such as heat or radiation. On the
other hand, it is also required for tissue development, such as the differentiation of fingers and
toes. The regular apoptosis is a highly controlled process and is not harmful to the organisms,
which makes it different from necrosis, another type of cell death.
The apoptotic process is controlled by diverse cell signals initiated both extracellularly
and intracellularly. Caspases are the major component of both pathways. According to the
position in the signaling pathway, human apoptotic caspases are divided into two groups.
Caspase-2, 8, 9, and 10 are initiator caspases because they are located on the upstream of the
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signaling cascade. Caspase-3, 6, and 7 are executioner caspases which are located on the bottom
of the cascade. Almost all healthy cells contain several caspases. These caspases, however, are in
their inactive zymogen form, named procaspases. All the procaspases consist of an N-terminal
domain and a catalytic domain formed by a big subunit p20 and a small subunit p10. The
primary structures of catalytic domains share high homology for all apoptotic caspases while
their N-terminal domains vary a lot. The initiator caspases usually contain large N-terminal
domains, such as the caspase recruitment domain (CARD) in caspase-2, -9, and a pair of death
effecter domains (DEDs) in caspase-8 and -10. These domains consist of specific protein-protein
interaction motifs that play crucial roles in the activation process. Upon the stimulation of cell
death signal, the N-terminal domains of initiator caspases will mediate the recruitment of the
procaspases to specific death signaling complexes. The procaspase molecules will subsequently
undergo self activation by ‘proximity-induced’ mechanism (Degterev, Boyce et al. 2003;
Fuentes-Prior and Salvesen 2004). In contrast, the executioner caspases only have short Nterminal domains and thus lack the capability of self activation in vivo. Their activation depends
on the cleavage of initiator caspases.
The apoptosis pathway initiated by extracellular signals is called the extrinsic pathway
(Fig 1.2) (Zhang, Hartig et al. 2005). It starts from specific molecules outside of the cells, known
as pro-apoptotic ligands. These ligands include Apo2L/TRAIL and CD95L/FasL. The proapoptotic ligand binds to their receptors on the cell surface. The receptor, known as death
receptor, is characterized by extracellular cysteine-rich domains (CRDs) and belongs to the
tumor necrosis factor (TNF) family of proteins (Lavrik, Golks et al. 2005). A number of death
receptors have been discovered, and some of them have been well studied, such as TNFR1 (p55
or CD120a), Fas (Apo1 or CD95), and TRAIL (R1/R2) (Yan and Shi 2005). All the death
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receptor proteins have a death domain (DD) in their intracellular domains. They are responsible
for binding adapter proteins during the caspase activation. The death ligands form homotrimers
when they are activated, which induces the oligomerization of death receptor upon binding. The
death domains of death receptor will subsequently bind to adaptor proteins such as FADD and
TRADD. These adapter proteins also have death domains and they interact with the death
receptor through homotyptic interactions (Cohen 1997). In addition, homotypic interactions are
also formed between the death effecter domains (DED) of the adaptor protein and the prodomain of procaspase-8, which leads to the oligomerization of procaspase-8 (Lavrik, Golks et al.
2005). Then, the death-inducing signaling complex (DISC) is formed. When the local enzyme
concentration of procaspase-8 is increased in the DISC, procaspase-8 molecules begin to cleave
each other, although a single procaspase-8 only has weak proteolytic activity (Lavrik, Golks et al.
2005). As a result, the active initiator caspase-8 molecules are released. In type I cells, once
caspase-8 is activated, it will start to process downstream executioner procaspases, including
procaspase-3, 6 and 7. After that, the active executioner caspases will cleave their substrates and
the apoptosis begins (Kumar 2007).
In the type II cells, the apoptosis signal coming from extrinsic death ligands is usually not
strong enough to trigger the entire apoptotic cascade. As a result, it requires another loop to
amplify the signal (Fig 1.2) (Zhang, Hartig et al. 2005). This loop is mitochondria-dependent
signal pathway which will be introduced in the next paragraph. The bridge between these two
pathways is built by a Bcl-2 family protein Bid. Following the activation, Bid will be cleaved by
active caspase-8. The truncated protein tBid in turn translocates to the mitochondria and starts
the apoptosis with other two Bcl-2 family members Bax and Bak (Yan and Shi 2005).
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Another type of apoptosis pathway is called the intrinsic pathway (Fig 1.2). This is
usually triggered by the death signals from inside the cells in response to diverse cell stresses,
such as DNA damage, a defective cell cycle, detachment from the extracellular matrix, hypoxia,
and loss of cell survival factors. The intrinsic apoptosis initiates from mitochondria and it is
regulated by Bcl-2 protein family. The Bcl-2 protein family is characterized by the conserved
Bcl-2 homology domain (BH) (Yan and Shi 2005). Over twenty Bcl-2 family members fall into
two categories, the pro-apoptotic Bcl-2 and the anti-apoptotic Bcl-2 (Kumar 2007). The antiapoptotic Bcl-2 proteins, such as Bcl-2 and Bcl-xL in mammals, reduce the permeability of
mitochondrial membrane and thus suppress the release of mitochondrial proteins. During
activation, the pro-apoptotic Bcl-2 proteins, such as Bax and Bak, will undergo homooligomerization. It is thought that these oligomers form pores which facilitate the release of
mitochondrial proteins, although the conclusive evidence is lacking (Yan and Shi 2005). With
the help of Bax and Bak, mitochondria proteins including cytochrome c and SMAC/DIABLO are
released into the cytosol. The SMAC/DIABLO can promote apoptosis by directly interacting
with inhibitor of apoptosis proteins (IAPs). The interaction interrupts the binding between IAPs
and caspases and thus activates caspases. Meanwhile, Cytochrome c binds the adaptor apoptotic
protease activating factor-1 (Apaf-1) to form a big multiprotein complex known as apoptosome.
The apoptosome is a key component of the intrinsic pathway because procaspase-9 is recruited
and activated from within the complex. Similar to the extrinsic pathway, the initiator caspase-9
will activate downstream executioner caspases upon maturation.
The other two initiator caspases are caspase-2 and caspase-10. The activation of caspase2 is similar to that of caspase-9. A big multiprotein complex is formed resembling the Apaf1/caspase-9 complex. The pro-domain of caspase-10 contains two DEDs, and its activation
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depends on the oligomeration process similar to caspase-8. The physiological functions of
caspase-2 and 10 in apoptosis, however, remain a matter of considerable debate (Kumar 2007).
Caspase-3 is a major executioner caspase that cleaves the majority of cellular substrates
in apoptotic cells. It can be activated by caspase-8 and 9 but not caspase-2 (Kumar 2007).
Previous study in caspase-3 mutant mice in genetically mixed 129/SvJ_C57BL/6 background
showed that mutant mice die prenatally due to reduced cell death in the central nervous system
(CNS). However, in pure C57BL/6 background, caspase-3 null animals are viable but show
reduced fertility. This comparison indicates that caspase-3 is redundant for most developmental
cell death (Lakhani, Masud et al. 2006). In addition, caspase-7 null animal also showed normal
development. In C57BL/6 background, Casp3/Casp7 double knockout (DKO) mice die rapidly
after birth. Cells from DKO mice showed resistance to extrinsic apoptosis but not intrinsic
apoptosis, although the activation of intrinsic apoptosis was delayed. It suggests that caspase-3
and 7 may amplify the signal of intrinsic apoptosis. Caspase-3, 6, and 7 share a similar structure,
but caspase-6 shows different substrate specificity from caspase-3 and 7. The function of
caspase-6 in apoptosis is still unclear. The mutation and knockout results suggest that one
executioner caspase may be most important in a particular cell death pathway while others are
either redundant or compensate. And their activities may be context dependent (Kumar 2007).
1.3. Caspase Substrate Specificity
Understanding the substrate specificities of caspases can help us to predict natural
caspase substrates and understand apoptotic signaling pathways. More importantly, it can
provide guidance for the design of inhibitors and drugs. This work can be done in two different
ways, either by investigating binding preferences in caspase active site grooves or by analyzing
the cleavage site sequences on their natural substrates. Obviously the first way is easier at the
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early stage of investigation as finding natural substrates of caspases is relatively difficult. In
1997, two different groups, Thornberry and Talanian, established the basic understanding of
caspase substrate preference by using synthetic peptide substrates (Talanian, Quinlan et al. 1997;
Thornberry, Rano et al. 1997). In the following years, the result was refined by a number of
studies, which led to a widely accepted understanding of caspase substrate specificity. As
illustrated in Figure 1.3, most caspases recognize tetrapeptide sequences. From the N-terminus to
the C-terminus, positions of each residue on the substrate are named P4, P3, P2, and P1. The
corresponding binding sites on the protein are named S4-S1. The enzyme can hydrolyze the
peptide bond after the P1 Asp. From P4 to P1, caspase-1,4,5,14 prefer W/YExD (x refers to any
amino acid); caspase-8,9,10 prefer I/LExD; caspase-3,7 prefer DExD; caspase-6 prefers VExD;
and caspase-2 prefers the pentapeptide substrate V/LDExD (Timmer and Salvesen 2007). Further
studies suggested that the P1’ residue (the residue after P1) is also important for substrate
specificity. For example, Gly, Ala, Thr, Ser and Asn are preferred at P1’ by caspase-3, while
bulky or charged residues were poorly tolerated (Stennicke, Renatus et al. 2000).
The traditional understanding of caspase substrate specificity has been verified by many
in vitro kinetic studies, however, it is vast oversimplified and dangerous to use for the prediction
of protein substrates (Timmer and Salvesen 2007). The presence of the preferred cleavage site
sequence is not sufficient for a protein substrate to be cut. The cleavage site must be properly
presented to the enzyme. The interactions between enzymes and larger substrates are usually
mediated by exosites distant from the catalytic site for many other regulatory proteases.
Although additional interactions between caspase and substrate have been suggested, the
mechanism still remains unrevealed. The crystal structure of p35 interacting with caspase-8 at a
surface area distant from the active site may suggests a possible exosite (Fisher, Cruz et al. 1999).
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In addition to exosites, the cleavage site sequences on caspase natural substrates also diverge
from canonical sequences. For example, about 45% of reported caspase-3 natural substrates
contain noncanonical cleavage site sequences (Fischer, Janicke et al. 2003). Thus, the preferred
cleavage site sequence on a protein is neither sufficient nor necessary to be a real cleavage site in
vivo. As the functions of caspases are better understood, more and more natural substrates of
caspases are being discovered. As discussed in a previous review (Earnshaw, Martins et al. 1999),
natural caspase substrates in apoptotic cells contain a wide range of proteins, including but not
limited to cytoskeleton proteins in cytoplasm, structural proteins in the nucleus, proteins
involved in DNA metabolism and repair, proteins involved in cell cycle regulation and
proliferation, proteins involved in signal transduction pathways, proteins related to human
genetic diseases, and proteins in the apoptotic regulation pathway. The identification of a real
substrate target is a challenging process with experiments from in vitro kinetic assay using
recombinant caspases to the test of cleavage site mutant transgenically introduced into whole
animals. Indeed only a small portion of the reported events are found to be significant in vivo.
Therefore, we must be aware that the published results have different levels of reliability and
they should not be considered equally for the analysis of caspase substrates.
The studies of caspase substrate specificity have been progressing for more than a decade.
They began from investigating the catalytic rates of different substrates. The preliminary
understanding helped the discovery of various natural caspase substrates, which in turn provides
valuable information for refining our understanding of caspase substrate specificity. In the
second round of investigation, we are studying the substrate binding from the structural point of
view. We hope that our study will provide valuable information to improve knowledge of
caspase substrate specificity.
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1.4. Caspase Inhibitors
Caspases are involved in apoptosis and inflammatory responses. They have been hot
targets of drug design for many years because dysregulation of caspase activity leads to many
severe diseases. Suppression of caspase activity is usually observed in cancer patients while
increased caspase activity is associated with many neuronal degenerative diseases and
autoimmune diseases, such as Parkinson’s disease (Blandini, Sinforiani et al. 2006), Alzheimer’s
disease (Blandini, Sinforiani et al. 2006), Huntington’s disease (Sanchez Mejia and Friedlander
2001), stroke (Schulz, Weller et al. 1999), and sepsis (Hotchkiss and Nicholson 2006). Although
caspase is a very attractive drug target and many inhibitors have been developed, no compound
has become an approved drug against caspase so far. Therefore, developing better caspase based
inhibitors is necessary for future drug development.
Current caspase inhibitors can be divided into three groups, natural inhibitor proteins,
substrate analog inhibitors, and non-peptide compounds. The most well known cellular caspase
inhibitors are the inhibitors of apoptosis protein (IAP) family. They are characterized by their
consensus N-terminal baculoviral inhibitory repeat (BIR) domains. XIAP is the most studied
family member. It has three BIR domains among which BIR2 is shown to inhibit caspase-3 and 7
while BIR3 can inhibit caspase-9. The functions of other IAPs, however, still remain unclear
(Eckelman, Salvesen et al. 2006).
Substrate analog inhibitors are usually peptides with ketone or aldehyde warheads. These
peptide inhibitors are not attractive for therapeutic development due to lack of specificity,
inhibiting all caspases and other cysteine proteases, or poor cell penetration and metabolic
stability. The mode of binding of peptide inhibitors has been studied in crystal structures, and
many structure based designs have aimed to reduce the peptidyl features (Weber, Fang et al.
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2008). This strategy has led to the identification of several effective substitutions for P2-P4
residues, as summarized in an earlier review (O'Brien and Lee 2004). Recently, a number of new
peptidomimetic caspase inhibitors were reported. One example is MX1153 (compound 1 in Fig.
1.4) (Wang, Guan et al. 2005). Although this inhibitor has fluoromethylketone as a warhead, it
showed >5000 fold IC50 for caspase-3 over several other cysteine proteases and serine proteases,
and reduced apoptosis in a mouse model. Another potent caspase-3 inhibitor M867 was
synthesized recently (Han, Giroux et al. 2005) (compound 2 in Fig 1.4). The P1 Asp was retained
in this compound, while the P2-P4 backbone was replaced by an amino pyrazinone template. The
hydrophilic furazanmethylamino showed the best binding affinity at P4, and at P2, the
hydrophobic t-Bu displayed the optimal whole cell activity, consistent with the substrate
specificity of caspase- 3. At the P1’ position, an N-methyl-N-hexyl group dramatically improved
cell permeability. Overall, M867 was highly effective in the in vivo anti-apoptosis tests (IC50 201200 nM). Interestingly, M867 was shown to be about 60-fold more effective against
recombinant caspase-3 versus caspase-7, and may facilitate the development of inhibitors
selective for caspase-3 rather than caspase-7, which has been a difficult issue for many years.
Other novel compounds are the aza-peptide inhibitors (Ekici, Li et al. 2006; Ganesan, Jelakovic
et al. 2006).These inhibitors carry P2-P4 peptide residues, but the P1 Asp is modified to aza-Asp
(Cα was replaced by N). Ketone and aldehyde were substituted with Michael acceptors as
warheads in these compounds, resulting in better selectivity against caspases over clan CA and
other clan CD proteases, such as legumain, clostripain, and gingipain K (Ekici, Li et al. 2006).
The interactions between these aza-Asp inhibitors and caspases are similar to those of
conventional tetrapeptide inhibitors at the P1-P4 positions, although the extension at P1’ allows
the exploration of the S1’ site of caspases. Crystal structures showed that the S1’ pocket of
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caspase-3 is surrounded by four loops forming an internal space of 900 Å3 (Ekici, Li et al. 2006).
Thr166 and Tyr204 are located at one side of this pocket and Phe128 and Met61 are on the other
side (Fig. 1.4B). Analysis of kinetic data and crystal structures suggested that a bulky
hydrophobic group can penetrate deeply into the S1’ pocket of caspase-3 forming favorable
interactions. Consequently, this inhibitor had enhanced binding affinities compared with
compounds with small P1’ groups. In contrast, caspase-8 has a relatively small S1’ site created
by Leu254, Ile257 and Tyr324 (Fig. 1.4B), and prefers small non-polar groups such as ethyl.
Enzyme inhibition assays suggested that caspase-7 has the same S1’ selectivity as caspase-3,
perhaps due to their highly homologous sequences; esters were the best candidates at P1’ for
caspase-2; ethyl was the optimal P1’ group for caspase-9 and 10; while there was no distinct S1’
selectivity observed for caspase-6 (Ekici, Li et al. 2006).
Parallel to the modification of peptidic inhibitors, potential caspase inhibitors have been
discovered by searching in the available chemical libraries. 5-nitroisatin was first discovered as a
nonpeptide caspase-3 inhibitor by using a highthroughput screen in the SmithKline Beecham
compound collection (Lee, Long et al. 2000). The modification of this compound led to the
development of a series of potent isatin analog inhibitors of caspase-3/7, including compound 3
in Fig. 1.5A with appKi values of 1.2 nM and 6 nM for caspase-3 and caspase-7, respectively
(Lee, Long et al. 2001). Kinetic data and crystallographic analysis on compound 5 in the
complex with caspase-3 indicated that a reversible covalent, tetrahedral adduct was formed
between the isatin carbonyl and the active site cysteine (Lee, Long et al. 2000). Unlike most
peptidomimetic inhibitors, the isatin inhibitors lack a P1 Asp and the caspase S1 pocket is thus
empty (Lee, Long et al. 2000) Fig. 1.5C. The pyrrolidine rings interact with caspase-3/7
primarily in the hydrophobic S2 pocket formed by three aromatic residues: tyrosine, tryptophan,
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and phenylalanine (Fig. 1.5D). Because caspases differ in their S2 pockets, this exclusive
binding profile of these inhibitors results in 1000-fold higher selectivity for caspase-3/7 versus
many other caspases (1, 2, 4, 6, and 8). This unique feature enables them to specifically inhibit
caspase-3 and 7, which has been unachievable by peptidomimetic inhibitors to date. Surprisingly,
a recent biochemical and biophysical study showed that compound 3 abolished caspase-3 activity
upon binding to only one active site of the homodimer (Aulabaugh, Kapoor et al. 2007). This
interesting phenomenon, however, was not observed in the previous crystal structure (Lee, Long
et al. 2000). Despite the ambiguities in the inhibition mechanism of isatin sulfonamide inhibitors,
their effectiveness in reducing apoptosis has been clearly demonstrated (Lee, Long et al. 2000;
Chapman, Magee et al. 2002). N1-substituted 5-pyrrolidinylsulfonyl isatins have been shown to
inhibit caspase processing in apoptotic endothelial cells (Kopka, Faust et al. 2006). For instance,
the compound (s)-(+)-5- [1-(2-methoxymethylpyrrolidine) sulfonyl]isatin (MMPSI) reduced
myocardial ischemic injury in an isolated rabbit heart model (Chapman, Magee et al. 2002). The
isatin sulfonamide compounds, which are potent and selective reversible nonpeptide caspase
inhibitors, have become good templates for structure-based drug design. Recently, modifications
at three different regions of an isatin sulfonamide molecule were evaluated for caspase-3/7
inhibition (Fig. 1.5A) (Chu, Zhang et al. 2005). In region I, neither substitution of the paraposition nor replacement with a pyridine ring significantly changed the inhibitory potency.
Nevertheless, a 20 fold lower potency was observed when the phenoxymethyl moiety in this
region was removed, indicating the hydrophobic group in region I possibly binds in the nonpolar S1’ site of caspase-3/7. In region II, the replacement of the pyrrolidine ring with an
azetidine ring did not improve the potency. In region III, the substitution of the benzene ring with
a pyridine ring increased the potency by 3-4 times against caspase-3/7, possibly due to the
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introduction of a hydrophilic interaction between the phenoxymethyl moiety and the S3 binding
pocket of caspase-3/7 (Chu, Zhang et al. 2005). An earlier study claimed that the in vivo
applications of isatin sulfonamide inhibitors may be limited because of the highly reactive nature
of their ketone carbonyl groups toward nucleophiles (Lee, Long et al. 2000). A possible solution
for this issue has been achieved recently by a new class of isatin sulfonamide analog compounds
called isatin Michael acceptors (IMAs) (Chu, Rothfuss et al. 2007). They contain Michael
addition acceptors as their warheads, which can be attacked by the thiol nucleophile of cysteine
(Fig. 1.5B). The binding affinities of certain IMAs, such as compound 4 in Fig. 1.5B, have
reached the nanomolar range against caspase-3/7. Interestingly, all IMAs showed 10-fold higher
potency for caspase-6 relative to their isatin sulfonamide analogs (Chu, Rothfuss et al. 2007).
This potency may provide a valuable hint for the design of caspase-6 inhibitors, which has
lagged far behind the development of caspase-3/7 inhibitors.
1,3-dioxo-2,3-diydro-1H-pyrrolo[3,4-c]quinoline (Fig. 1.6B) was recently discovered as a
small molecule inhibitor of caspase-3/7. It represents a novel scaffold for non-peptide inhibitors
of executioner caspases. A number of derivatives varying at the R1, R2 and R3 positions were
synthesized and evaluated in caspase-3 in vitro inhibition assays (Kravchenko, Kysil et al. 2005).
Compound 6 with the combination of a morpholinesulfonyl moiety at position R1 and 1,3,5trimethyl-1H-pyrazol-4-yl group at R2 was the lead compound among those tested when R3 was
fixed to –CH3 (Fig. 1.6A) (Kravchenko, Kysil et al. 2005). It showed an IC50 value of 4 nM
against caspase-3, comparable to the commercial tetrapeptide inhibitor Ac-DEVD-CHO
(IC50=3.1 nM under the same conditions). The best R3 moiety was examined by fixing R1 and
R2 groups. Methyl group and phenyl group displayed the best IC50 values of 23nM and 27nM,
respectively (Kravchenko, Kuzovkova et al. 2005). Overall, the best combination of R1-R3 is
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shown in compound 8 in Fig. 1.6A, however, its activity remains to be determined. The
inhibitory mechanism of this class of inhibitors has been suggested to arise from nucleophilic
attack of the caspase catalytic cysteine on the ‘phthalimide’ carbonyls (Kravchenko, Kysil et al.
2005) (Fig. 1.6B). However, the mode of binding of these inhibitors has not been confirmed due
to the absence of structural evidence. In addition, recent kinetic studies indicated that these
compounds were noncompetitive reversible inhibitors for caspase-3 (Kravchenko, Kuzovkova et
al. 2005), implying that they do not bind in the active site groove of caspase-3 or interact with
the catalytic cysteine. Possibly these compounds bind in another region of caspase-3, such as the
allosteric binding site. Further insights into the mode of binding of these inhibitors could lead to
the discovery of new inhibitory mechanisms. Another subset of this class of inhibitors is the
isoquinoline-1,3,4-trione (compound 9) derivatives (Chen, Zhang et al. 2006). The best
compound (compound 10) showed a comparable potency against caspase-3 to that of the peptidic
inhibitor Ac-DEVD-CHO. Although, most of these compounds demonstrated better activities
against caspase-3/7 over other caspases, the differences were not sufficient to ensure selectivity.
However, some isoquinoline-1,3,4-trione derivatives specifically inactivated caspase-1 (Ma,
Zhang et al. 2007). Importantly, this class of compounds showed 50-1000 fold higher
specificities against caspases relative to other cysteine and serine proteases (Chen, Zhang et al.
2006). The compounds were validated in PC21 cells and primary neuronal cells, where they
effectively attenuated apoptosis induced by the amyloid-beta protein that is released by caspase-3
in the progression of Alzheimer’s disease (Zhang, Zhang et al. 2006). Enzyme kinetic studies
indicated that these compounds performed as noncompetitive inhibitors (Chen, Zhang et al. 2006)
and they bound to caspases irreversibly in a slow-binding manner (Zhang, Zhang et al. 2006).
The binding mode of these compounds is unknown. Therefore, the future development of these
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promising quinoline derivatives would benefit greatly from structural analysis of the caspaseinhibitor complexes.
Despite substantial efforts, relatively few compounds targeting caspases are currently in
clinical trials. The caspase inhibitors VX-765 (Fig. 1.7 compound 11), VX-740, and MX-1013
were reviewed previously (Callus and Vaux 2007). Caspase-1 inhibitor VX-756 is in Phase II
clinical trials for the treatment of inflammatory diseases (Fischer and Schulze-Osthoff 2005).
VX-799, a small molecule pan caspase inhibitor developed by Vertex/Serono for septic organ
failure, is in Phase I clinical trials. The pan caspase inhibitor IDN-6734 developed for the
treatment of acute myocardial infarction is also in Phase I clinical trials (Fischer and SchulzeOsthoff 2005). IDN-6556 (Fig. 1.7 compound 12) is an oxamyl dipeptide pancaspase inhibitor
(O'Brien and Lee 2004) with promising results in Phase I clinical trials (Callus and Vaux 2007)
and in Phase II clinical trials in patients with liver transplants (Baskin-Bey, Washburn et al.
2007). Also, IDN-6556 is promising as a potential drug for chronic hepatitis C (Pockros, Schiff
et al. 2007).
Information from crystal structures of caspase complexes has proven valuable in the
design of more selective and potent caspase inhibitors such as the aza-peptides with Michael
acceptors, and the non-peptide isatin derivatives, and for the design of SMAC mimics to activate
caspases. In parallel, structure-based screening of chemical libraries has identified novel
compounds to control caspase activity like the isatin derivative inhibitors and the activator
embelin. Overall, the development of pharmacological agents to control caspase mediated cell
death has greatly benefited from structural studies, and several compounds are in clinical trials or
preclinical development for treatment of various diseases.
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1.5. Protein Crystallography and Caspase Structures
Determining protein 3D structure can help the understanding of protein functions and
thus is a critical component of proteomics. Two methods are currently widely used for
determining protein structures, X-ray protein crystallography and nuclear magnetic resonance
(NMR). The basics of X-ray crystallography were established by a number of scientists in the
early twentieth century, but this technique was not used on investigating protein structures until
1950s’. By first solving the structure of sperm whale myoglobin using X-ray crystallography,
Max Perutz and Sir John Cowdery Kendrew were awarded the Nobel Prize in Chemistry in 1962.
In the following half century, protein crystallography technique has been significantly improved
in respect to both accuracy and efficiency. Today protein crystallography has become an almost
routine technique in biological studies. Compared with NMR, crystallography has no limitation
on the size of macromolecules, thus it is becoming more and more popular. According to the
protein data bank (www.pdb.org), 52025 structures of biological macromolecules have been
determined by X-ray crystallography by Sep-29-2009.
Protein crystal is a solid material where protein molecules are arranged in an orderly
repeating pattern extending in all three spatial dimensions. When an X-ray beam strikes a crystal,
it will be diffracted into many specific directions. By analyzing the diffraction pattern, a
crystallographer can determine the positions of protein atoms in the crystal. The basis of protein
crystallography is the Bragg’s law (nλ = 2 d sinθ) whose principle is shown in the Figure 1.8b.
Crystal is formed by highly ordered repeats of unit cells (Figure 1.8a). We can consider the
atoms 1 and 1’ in the figure 1.8b as equivalent atoms in two repeated unit cells. When an X-ray
beam strikes on these two atoms, there will be two reflections (a and b) generated by the
reflection planes (m and m’). Because X-rays are a type of electromagnetic wave, the amplitudes
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of a and b will be amplified if they are in the same phase when they reach the detector. In
contrast, their amplitudes will be canceled out if they are in opposite phases. According to
Bragg’s law, if the difference (2l in the figure 1.8b) between the pathlengths of a and b equals nλ
(n is any integer, λ refers to the wave length) then a and b will have the same phase when they
reach the detector. This means we can find the right angle θ by simply rotating the crystal
because λ and d are constants for a particular experiment. Since every equivalent atom 1 in each
unit cell will generate a reflection, once the X-rays strike the crystal from the right angle θ, the
amplitudes of all these reflections will be summed up on the detector and thus form one bright
spot. On the other hand, reflections generated by nonequivalent atoms will not form a spot
because their amplitudes will be canceled out due to different phases. The intensity of a spot is
proportional to the square of the amplitude of the diffracted wave. The intensities together with
the phase angles can be transformed by Fourier Transformation into 3D visualizations of electron
surfaces of atoms, called electron density map. As a result, the position of each atom can be
determined.
Protein crystallography, although useful, is a challenging technique because several
bottlenecks limit its success rate. For example, growing diffraction quality crystals, including
previous protein expression and purification, finding appropriate cryoprotectant, and phasing are
all very challenging tasks. The entire process of protein crystallography includes the following
steps: crystallization, data collection, phasing, modeling, and refinement.
Crystallization is the first and the most difficult step. Normally, proteins can form into
crystals in very particular conditions depending on protein concentration, pH, salt, temperature,
buffer, precipitant, and addictives. Crystallization conditions of different proteins normally vary
a lot from one to another. Even single residue mutation or replacement of a small ligand can
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dramatically change the crystallization condition. Therefore a standard crystallization protocol
does not exist, and one successful crystallization usually comes out of hundreds even thousands
of failures. Crystallization techniques fall into several categories, vapor diffusion, batch, and
dialysis. The vapor diffusion method is the most widely used method. Taking hanging drop
method as an example, the principle of vapor diffusion is illustrated in Figure 1.9a. The sealed
system contains reservoir solution in a small well covered by a glass coverslip. The reservoir
solution consists of buffer, precipitant, and sometimes addictives. A small amount (1-2µl) of
protein solution is mixed with equal amount of reservoir solution and suspended as a droplet
underneath the coverslip. Because the precipitant concentration in the droplet is lower than that
in the reservoir solution, water in the droplet will slowly evaporate and migrate into the reservoir
until the system equilibrates. As a result, protein concentration in the droplet will gradually
increase. If the final concentrations of protein and precipitant are optimal, protein crystals will be
formed (Rhodes 2000). A picture of protein crystals is shown in the Figure 1.9b.
The second step is data collection. Because low temperature can increase the stability of
molecules and thus enhance diffraction quality, X-ray diffraction data are currently collected
with the help of liquid nitrogen (boiling point -196°C). Therefore, the protein crystal needs to be
mounted on to a fine glass capillary loop with the reservoir liquid and frozen in the liquid
nitrogen before the diffraction experiment. The freezing step requires the protection of
cryoprotectant, which is some chemical agent that prevents the formation of both crack and ice in
the protein crystal during the flash freezing in liquid nitrogen. Regular cryoprotectants include
glycerol, small molecular weight polyethylene glycol, sugar, and some oils. Because the type and
concentration of cryoprotectant and the appropriate procedure for freezing crystals vary from
crystal to crystal, the cryoprotection is also a challenging step. During the data collection, the
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crystal is placed in front of an X-ray detector. Following the Bragg’s law, an X-ray beam will be
diffracted into many particular directions after striking the crystal and thus form spots on the
detector. The detector will record the diffraction pattern as one diffraction frame. The crystal is
rotating during the data collection. In order to determine the 3D structure of the protein, a large
number of frames must be taken at different angles. Because long-term X-ray radiation can
damage the alignment of crystal cells, the aim of data collection is to accomplish the highest
resolution and completeness within the shortest time.
To solve the protein structure, both diffraction density and phase are required. However,
the phase cannot be measured directly in the experiment and it needs to be deduced indirectly.
Actually, the phasing problem is the second serious bottleneck of crystallography. There are two
basic approaches to solve the phasing problem: one is to perturb the structure and diffraction, and
the other is to guess the phases. Two methods are widely used for the first approach: multiple
isomorphous replacement and multiple wavelength anomalous dispersion. The isomorphous
replacement is a classic phasing method. It uses a crystal nearly identical to the one being studied,
except that there are several atoms replaced or added. Usually heavy atoms are co-crystallized or
soaked into the crystal where they can bind tightly with the protein. These heavy atoms can
perturb the diffractions and their positions are likely to be deduced. From positions of heavy
atoms, phases of other protein atoms can be deduced. Because replacing or adding atoms can
disturb structures of nearby protein atoms, the isomorphism is never perfect. The multiple
wavelength anomalous dispersion (MAD) then becomes a substitution. In this method, only one
crystal is studied. It contains atoms called anomalous scatterers, such as selenium. The degree to
which the anomalous scatterers perturb the diffraction pattern can be changed by using different
X-ray wavelengths. In this way, the position of anomalous scatterers can be deduced. This
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method is more accurate than the isomorphous replacement because all the experiments are done
on one crystal. In contrast to deduction, phase can be solved more efficiently by guessing
sometimes, especially when the protein structure has been solved in another crystal form, or the
protein sequence is similar to another protein (identity > 25%) with known structure. In this case,
the known structure can be used as a template to guess the phase of the current crystal by using
rotation and translation functions (Blow 2002).
When the phase problem is solved, the diffraction data can be transformed into electron
density map by using Fourier transform (Sherwood 1976):

ρ ( x, y , z ) =

1
Fhkl e −2 πi ( hx + ky +lz )
∑∑∑
V h k l

According to Fourier transform, the electron density function ρ (x,y,z) can be determined by the
volume of the unit cell V, structure factor Fhkl, and the phase. The structure factor is calculated by
the following equation:

Fhkl = ∑ f j e 2 πi ( hxj + kyj +lzj )
j

In the equation, the parameter fj refers to scattering factor of a particular atom j.
Based on the electron density map, a protein structural model can be built. Usually the
main chain atoms of the protein are first fitted into the electron density map. Side chain atoms
are then added one by one according the protein sequence. Building structural model is much
more straightforward for molecular replacement because most atoms would have been positioned
after the phasing. Normally, high resolution data can provide more detailed and confident
information to the protein conformations. Roughly speaking, the overall shape of a protein can
be seen with the data of resolution 5.5 Հ; main chain structures can be determined with
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resolution of 3.5 Հ; side chain conformations can be determined with resolution of 2.5 Հ; and
positions of single atoms can be determined with resolution of 1.5 Հ or better. Since this step is
relatively straightforward, some software has made it automatic, such as ArpWarp (Lamzin and
Wilson 1993) and Coot (Emsley and Cowtan 2004).
The last and most tedious step is the model refinement. In this step, the conformation of
each individual residue needs to be examined. If the model structure does not fit the electron
density perfectly, then it needs to be adjusted as close to the density map as possible.
Subsequently, new electron density map will be calculated based on adjusted model. This
process needs to be repeated many times until the discrepancy R between the X-ray structure
factors calculated for the model structure |Fcal| and the observed intensities |Fobs| drops to a
reasonable lever ( R =

∑

h

Fobs − Fcal

∑

h

Fobs

< 0.25 ). Usually a protein has one to several hundreds of

residues, therefore the refinement process can last days to weeks.
3D structures of six caspases family members have been determined using X-ray
crystallography, including caspase-1, 2, 3, 7, 8, and 9 (Yan and Shi 2005). The structures of
other caspases still remain unclear. All the identified mature caspase structures share similar
overall structure. In most caspase structures, a heterotetramer is formed by two caspase
molecules, each of which contains a big subunit p20 and a small subunit p10. The active site
cysteine is surrounded by loops, forming the substrate binding pocket. The structures of six
caspase family members are shown in the Figure 1.10.
1.6. Protein Structure Prediction and Potential Functions
The number of proteins discovered in different species is growing very fast because of
the development of new techniques for investigating biological mechanisms. The determination
of protein structures, however, lags behind due to the efficiency limit of current experimental
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techniques for structural determination. Fortunately, it is believed that proteins always fold into
their 3D structures by following certain physical and chemical rules. Roughly speaking, a protein
molecule always folds into the most stable conformation in a certain environment, which means
the internal energy of a protein molecule is the lowest in its native conformation. Therefore, the
protein structure can be predicted by simply comparing the internal energies of all possible
conformations. With the help of modern computers, protein structure prediction, or structural
modeling, has made great contributions to the understanding of protein structures and functions.
The internal energy of a protein molecule cannot be directly measured in the experiment.
It is thus approximated by mathematical functions. One type of potential functions is derived
from physical laws and they are called empirical potentials. Normally, the molecular system is
represented in atomic level for molecular mechanics and electronic level for quantum mechanics.
In the molecular mechanics, atoms are typically described as points with certain charges and
masses. Their positions are represented by coordinates in Cartesian space (Erkoc 2001). The
interactions between atoms include bonded interactions and nonbonded interactions. The bonded
interaction is usually represented with a quadratic expansion around the equilibrium bond
distance. Similar functions are used to represent other aspects of covalent geometry such as
bond angles, planarity, chirality and torsional (around bond) rotations. The nonbonded
interactions, including van der Waals interactions (attractive and repulsive force between
molecules) and electrostatic interactions, are normally described by the Lennard-Jones potential
and the Coulomb's law, respectively. Total potential energy of a protein molecule is determined
by the summation of the bonded and non-bonded energies (Erkoc 2001). This type of potential
function has large complexity and moderate accuracy.
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Another type of potential energy function is named knowledge-based potentials (or
statistical potentials). It differs from the empirical potentials in developing potential functions
using statistical approaches but not physical rules. Based on the assumption that a protein
molecule always folds into its native structure with the lowest potential energy in native
conditions, computers can be trained to develop statistical potential functions to discriminate the
native structure (experimentally determined protein structure) from structural models having
different conformations (known as decoys). These potential functions, therefore, can be applied
for evaluating the qualities of predicted protein structural models. More specifically, lower
potential energy reflects better quality for a structural model, or verse visa. Many knowledgebased potentials have been developed. In some methods, a single point is used to represent the
position of a residue. Different methods use different residue representation, such as Ca atom, Cb
atom, or side chain center of mass (SCM) (Zhang, Liu et al. 2004). The entire potential energy of
a protein is calculated as the summation of the energy between each residue pair. These methods
are thus residue level potentials, such as RAPDF-SCM (Samudrala and Moult 1998), KBP-SCM
(Lu and Skolnick 2001), and DFIRE-SCM (Zhang, Liu et al. 2004). In order to achieve better
accuracy, many methods calculate the potential energy based on each atom pair. These methods
are named atomic level potentials, such as DFIRE-A (Zhou and Zhou 2002), and Atomic KBP
(Lu and Skolnick 2001).
The knowledge-based potentials are developed by using machine learning techniques,
where training data has large impact on the accuracy of the potential functions. The training data
normally consists of decoy sets. Each decoy set contains one native structure of a protein and a
certain amount (from less than one hundred to thousands) of distinct structural models of the
same protein. Decoy structures are generated by using different algorithms. Commonly used

24
decoy sets include lattics_ssfit (Xia, Huang et al. 2000), lmds (Keasar and Levitt 2003), and
Rosetta (Simons, Bonneau et al. 1999), etc. Hidden features of the native protein structure can be
extracted by machine learning methods, such as genetic algorithm which is a widely used
machine learning technique for searching exact or approximate solutions to optimization
problems (Banzhaf, Nordin et al. 1998). The extracted hidden feature can be consequently
integrated into potential functions to discriminate the native structure and closely similar
structural models from other models. Although traditional knowledge-based potentials have
better computational efficiency and cover hidden features of protein structures, the potential
functions themselves are less physically meaningful and cannot be used for molecular mechanics.
Therefore, this method still needs to be improved.
1.7. Objectives
Although a tremendous mount of effort has been put into the development of caspasebased drugs for over a decade, no caspase-based drug is yet available. Major challenges for drug
development include cell permeability, metabolic stability, and target specificity. Since a large
number of caspase inhibitors have been developed (Weber, Fang et al. 2008), a potential drug is
likely to be obtained by modifying these caspase inhibitors. Structural information of
substrate/inhibitor binding in caspases can provide valuable guidance in the design of the next
generation of drug candidates. Therefore, this study aims to help the future caspase-3 based drug
design from two aspects. First, the structural basis of caspase-3 substrate binding at P1-P5 will
be investigated by analyzing crystal structures of caspase-3 bound with its substrate analog
inhibitors. Second, novel knowledge-based potential functions will be developed in order to
facilitate the prediction of protein structures and protein-ligand structures.
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Figure 1.1. Grouping of 14 mammalian caspase family members (Lavrik, Golks et al. 2005).
Colorful blocks refer to different domains.
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Figure 1.2. Extrinsic and intrinsic signaling pathway of apoptosis (Zhang, Hartig et al. 2005).
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Figure 1.3. Schematic presentation of caspase substrate binding site. The substrate
specificities of caspases are shown in the Table where X refers to any amino acid.
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Figure 1.4. Peptidomimetic inhibitors. A. MX1153 and M867 are two examples of
peptidomimetic inhibitors of caspase-3. B. The binding of aza-peptide inhibitors in caspase-3
(PDB code 2C2M) and caspase-8 (PDB code 2C2Z). Side chains of caspase S1’ residues are
shown in stick format and labeled with residue names. The aza-peptide Michael acceptor
inhibitors are shown in stick format and their P1’ groups are labeled.
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Figure 1.5. Isatin sulfonamide analog inhibitors. A. Isatin sulfonamide analog inhibitors of
caspase-3/7. I, II, and III indicate three groups modified in later studies (12,49). B. IMA inhibitor,
and proposed reaction mechanism with caspases. C. Crystal structure of 1GFW shows the
binding mode of compound 5 in caspase-3. Caspase-3 active groove is in a surface representation.
S1’~S4 binding pockets are labeled. D. Schematic representation of interactions between
inhibitor 5 and caspase-3. Hydrogen interactions are shown in dashed lines. Caspase-3 S2
residues having non-polar interactions with inhibitor 5 are labeled.
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Figure 1.6. Quinoline derivative inhibitors. A. Modification of a general quinoline derivative
inhibitor led to the discovery of two potent caspase-3 inhibitors, compounds 6 and 7. Compound
8 suggests a putative better inhibitor. B. Putative inhibitory mechanism of quinoline inhibitors
against caspases. C. Compound 10 is an example of isoquinoline inhibitor derived from
compound 9.
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Figure 1.7. Structures of VX-765 and IDN-6556. Structure of VX-765 (11) and IDN-6556 (12)
in clinical trials.
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Figure 1.8. Crystal packing and the Bragg’s law. (a) Packing of protein crystals. (b)
Schematic presentation of the Bragg’s law.

33

Figure 1.9. Hanging drop vapor diffusion system and crystal samples. (a) Hanging drop
vapor diffusion system. (b) Protein crystals of caspase-3/DMQD complex under microscope.
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Figure 1.10. The list of caspase structures currently deposited in PDB. The structures are in
ribbon representation and rainbow coloring.
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2. CASPASE-3 BINDS DIVERSE P4 RESIDUES IN PEPTIDES AS REVEALED BY
CRYSTALLOGRAPHY AND STRUCTURAL MODELING
2.1. Introduction
Caspases are key effectors in the processes of apoptosis and inflammation. The family of
cysteine aspartyl proteases comprises 14 mammalian caspases that are divided into three groups
according to their structure and role in the apoptotic and inflammatory pathways. The first group
consists of inflammatory caspase-1, 4, 5, and 11 (Martinon, Holler et al. 2000). They play
essential roles in cytokine maturation and inflammatory responses. The second and the third
groups are involved in the apoptotic process. Caspase-2, 8, 9, 10, and 12 are called initiator
caspases because they are located on the upstream of the signaling pathway. They initiate the
apoptotic cascade upon receiving interior or exterior death signals. Caspase-3, 6, 7, and 14 are
downstream caspases that are activated by initiator caspases during apoptosis. The mature
proteins are called executioner caspases because they selectively hydrolyze cellular proteins in
the pathways leading to cell death. Several hundred different proteins have been identified as
caspase substrates, as reviewed in (Fischer, Janicke et al. 2003; Timmer and Salvesen 2007).
Caspase activity is highly regulated in the cell. Some natural caspase regulators have
been identified, such as caspase recruitment domains (CARD) and inhibitor of apoptosis proteins
(IAPs), however, the entire regulatory machinery is very complicated and not yet fully
understood. Dysregulation of caspase activity is associated with many severe human diseases.
For example, neuronal crush injury, stroke, heart failure and neurodegenerative diseases such as
Alzheimer’s, Parkinson’s, and Huntington’s diseases are associated with increased activities of
caspases (Hartmann, Troadec et al. 2001; Hermel, Gafni et al. 2004; Tacconi, Perri et al. 2004).
On the other hand, caspase activity is suppressed in cancer, autoimmune diseases and viral
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infections (Vucic, Stennicke et al. 2000; Lakhani, Masud et al. 2006; Volkmann, Cornberg et al.
2006). The development of caspase inhibitors as potential drugs has attracted great attention.
Several non-peptide caspase inhibitors are currently in clinical trials, such as IND6556 and VX740 (O'Brien and Lee 2004; Callus and Vaux 2007).
Caspase recognition of substrates has been investigated in order to identify the caspasemediated pathways leading to cell death as well as to facilitate drug development. Early studies
on peptides showed that caspases recognize at least four residues from P1 to P4, and they
exclusively require aspartic acid at P1 in their substrates. From P2 to P4, different caspases have
distinct preferences. Caspase-1, 4, and 5 were shown to prefer the tetrapeptide sequence WEHD.
Caspase-2, 3, and 7 prefer DEXD, whereas, caspase-6, 8, and 9 prefer (L/V)EXD (Thornberry,
Rano et al. 1997; Lavrik, Golks et al. 2005). However, a series of recent studies have questioned
these preferences. For example, the application of substrate-phage approach implied that DLVD
was hydrolyzed up to 170% faster than canonical caspase-3 substrate DEVD (Lien, Pastor et al.
2004). A computer based virtual screen found a potent caspase-3 inhibitor Ac-DNLD-Cho with
comparable inhibition to Ac-DEVD-Cho. Similarly, Ac-DFPD-Cho was found to be the best
tetrapeptide inhibitor for caspase-7 (Yoshimori, Sakai et al. 2007). Moreover, a non-polar P5
residue was shown to facilitate substrate recognition of caspase-2 and 3, while polar P5 is
preferred by caspase-6 (Schweizer, Briand et al. 2003; Fang, Boross et al. 2006). Since many
caspase substrates are observed with diverse non-canonical sequences at their cleavage sites
(Backes, Kuentzer et al. 2005), it is apparent that the substrate selectivity of caspases is still
poorly defined.
Caspase-3 is one of the critical executioner caspases. Previously, we analyzed the S2, S3
and S5 pockets of caspase-3 using aldehyde peptidyl inhibitors Ac-DEVD-Cho, Ac-DMQD-Cho,
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and Ac-VDVAD-Cho (17). Analysis of the P5 interaction in S5 was extended to the Ac-LDESDAc complex (Fu, Chumanevich et al. 2008). The complexes with non-canonical P4 residues in
the S4 pocket of caspase-3 have not been analyzed, due to the assumption that P4 Asp was
critical for substrate binding (Stennicke, Renatus et al. 2000). Although P4 Asp is common,
many other amino acids, including hydrophobic residues, can be found at the P4 position in the
known protein substrates of caspase-3 (Fischer, Janicke et al. 2003). Evidently, P4 Asp is not
essential for substrate recognition and hydrolysis. In addition, the analysis of non-polar residues
in the S4 pocket is important for development of inhibitors into drugs, because hydrophobic
moieties provide better cell permeability in drugs. Therefore, the binding of P4 residues was
studied with the dual aims of helping to identify natural caspase-3 substrates and to design new
inhibitors and drugs. Previous structural studies have focused on peptide with P4 Asp. The
plasticity of the S4 pocket was studied in four caspase-3 crystal structures with inhibitors AcIEPD-Cho (IEPD), Ac-WEHD-Cho (WEHD), Ac-YVAD-Cho (YVAD), and Boc-D(OMe)-Fmk
(BocD). This crystallographic analysis was combined with molecular mechanics energy
calculations on structural models of P4 residues in relation to enzyme inhibition data, and
suggested that S4 pocket of caspase-3 can accommodate a variety of residues with different
affinities.
2.2. Materials and Methods
2.2.1. Plasmids and Recombinant Proteins
The cloned full length human caspase-3 cDNA was expressed in E.coli BL21(DE3). The
over-expressed protein was purified using nickel affinity chromatography, ion exchange
chromatography, and gel-filtration chromatography as previously described (Fang, Boross et al.
2006). Protein was concentrated to 4 mg/ml and stored at -80 °C. The purity was determined to
be over 99% by SDS-PAGE.
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2.2.2. Enzyme Kinetic Assays
The inhibition constants of reversible aldehyde caspase-3 inhibitors Ac-IEPD-Cho, AcWEHD-Cho, and Ac-YVAD-Cho were measured using the same protocol as previously
described (Fang, Boross et al. 2006). Briefly, caspase-3 was preincubated with its inhibitors in
reaction buffer (50 mM HEPES, 100 mM NaCl, 0.1% CHAPS, 10% glycerol, 1mM EDTA and
10 mM dithiothreitol, pH 7.5) at room temperature for 15 mins. Then, substrate was added and
reaction velocity was calculated from p-nitroanilide released by enzyme cleavage as measured at
a wavelength of 405 nm using a Polarstar Optima microplate reader (BMG Labtechnologies,
NC). The inhibition constants of each inhibitor were determined by a dose-response curve
described by the equation: Ki = (IC50-0.5[E])/(1+[S]/Km), where [E], [S] and IC50, respectively,
correspond to active enzyme concentration, substrate concentration, and the inhibitor
concentration needed to suppress half enzyme activity (Maibaum and Rich 1988). The enzyme
concentration was determined by active site titration against Ac-DEVD-Cho using method
described previously (Donepudi, Mac Sweeney et al. 2003). The inhibition profile of irreversible
inhibitor BocD was obtained using the same method and 30 mins preincubation. Time
dependence of the initial velocity was measured using 300 nM of caspase-3 and a constant
amount (2µM) of BocD after preincubation for times from 0 to 60 mins.
2.2.3. Crystallographic Analysis
The inhibitors were dissolved in dimethylsulfoxide. Caspase-3 was incubated at room
temperature with the inhibitor at 10 to 20-fold molar excess. Crystallization was performed by
the hanging-drop vapor diffusion method. Specifically, 1 µl of protein solution (4 mg/ml) was
mixed with an equal volume of mother liquid (100 mM sodium citrate, 5% glycerol, 10 mM
dithiothreitol, and 14-18% PEG6000, pH 6.5). Crystals grew within 24 hrs at room temperature.
The crystals were frozen in liquid nitrogen with 20% glycerol as a cryoprotectant. X-ray
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diffraction data were collected on the SER-CAT beamline at the Advanced Photon Source,
Argonne National Laboratory.
The diffraction data were processed with HKL2000 (Otwinowski 1997). The structures
were solved by molecular replacement with the program AmoRe (Navaza 1994). The structure of
caspase-3/DMQD (PDB code 2H5J) was used as the initial model for all the structures in this
study. All the structures were refined using CNS (Brunger, Adams et al. 1998). The molecular
graphics program O 8.0 (Jones, Zou et al. 1991) was used to display the electron density map and
to refit structures. Water molecules and alternate conformations of caspase-3 residues were
modeled when observed in the election density maps. Structural figures were made by Weblab
viewer pro (Accelrys Inc., MA) and images of electron density map were obtained using
Molscript (Esnouf 1997; Esnouf 1999). The crystal structures have been deposited in the RCSB
Protein Data Bank with accession codes 3GJT for caspase-3/IEPD, 3GJQ for caspase-3/WEHD,
3GJS for caspase-3/YVAD, and 3GJR for caspase-3/BocD.
2.2.4. Molecular Modeling
Models of caspase-3 complexes with inhibitors of the form Ac-XEVD-Cho, where X is
one of the 20 amino acids, were built using the program AMMP (Harrison 1993). The models
were generated from the crystal structure of caspase-3/DEVD (Fang, Boross et al. 2006), which
comprises the DEVD inhibitor bound to one large and one small subunit of a caspase-3
heterodimer. The other P4 residues were introduced into the inhibitor using Coot (Emsley and
Cowtan 2004). The hydrogen atoms were built with the sp4 potential set using 15 cycles of the
analytic model building algorithm in AMMP (Bagossi, Tozser et al. 1999; Harrison 1999),
followed by conjugate gradients minimization of the non-bonded and geometrical terms. Finally,
each caspase-3/inhibitor complex was optimized by 1000 steps of conjugate gradients energy
minimization. The total non-bonded interaction energy was calculated for each caspase-peptide
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model. Structural models were examined with the molecular graphics program RasMol (Sayle
and Milner-White 1995) on Linux PCs. The experimental binding energy was calculated as ΔG =
RT lnKi from the seven measured inhibition constants for correlation with the calculated
interaction energies. The regression line from this correlation was used to predict Ki values for
the peptides with other P4 residues from the peptide-caspase interaction energies calculated by
the modeling program.
2.3. Results
2.3.1. Analysis of P4 Residues in Known Caspase-3 Substrates
The frequency of occurrence of different P4 amino acids was analyzed for 182 natural
substrates of caspase-3 listed in (Fischer, Janicke et al. 2003). Almost all amino acids can be
found at least once at the P4 position as shown by the relative occurrence (Fig. 2.1). Aspartic
acid was the most frequent residue in this position appearing in 55% of the substrate cleavage
sites. The other cleavage sites had sixteen different residues at the P4 position, comprising 29%
polar and 16% nonpolar residues. Glu and Ser are ranked second and third in frequency after Asp,
appearing in 10% and 9 % of cleavage sites, respectively. Hydrophobic residues appear in the
relative frequency of Val > Ala > Leu > Met > Phe > Ile/Cys. None of the 182 proteins had Arg,
Lys, or Gln at P4, so these positively charged or polar amino acids are likely to be rare in
caspase-3 cleavage sites. Therefore, in normal physiological conditions, the S4 pocket of
caspase-3 can accommodate a variety of residues including the preferred negatively charged Asp,
small polar and a variety of hydrophobic side chains.
2.3.2. Inhibition Constants of Caspase-3 Inhibitors
Seven substrate analog reversible inhibitors of caspase-3 are commercially available.
They were divided into two groups based on their P4 residues. DEVD, DQMD, and DMQD are
caspase-3/7 inhibitors with the standard motif of DxxD; while IEPD, ESMD, WEHD, and
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YVAD possessing different P4 residues are optimal inhibitors of initiator caspase-8 and
inflammatory caspases. The kinetic study was performed using the canonical caspase-3 substrate
Ac-DEVD-pNA with the Km value determined as 62.5±2.5 µM. The inhibition constants of the
seven inhibitors against caspase-3 are listed in Table 2. The first group of inhibitors with the
standard P4 Asp exhibited potent inhibition with Ki values from 1.2 nM for DEVD to 12 nM for
DMQD, whereas the second group of inhibitors had Ki values approximately a thousand times
weaker. In the second group, IEPD was the most potent with the Ki value of 1.2 μM, while
YVAD was the weakest with Ki of 10 μM. The inhibition values are comparable with those of
previous studies with fewer inhibitors showing Ki values of 0.2-1nM for DEVD, 195 nM for
IETD, 1.9 μM for WEHD and 10-12 μM for YVAD (Nicholson, Ali et al. 1995; Talanian,
Quinlan et al. 1997; Garcia-Calvo, Peterson et al. 1998).
BocD is a pan-caspase irreversible inhibitor widely used for in vivo studies. Its inhibitory
profile was compared with IEPD as shown in Fig. 2.2a. At low inhibitor concentration, the
enzyme activity was insensitive to the inhibitor. However, a substantial decrease of enzyme
activity was observed when the inhibitor concentration was raised to 1 µM. The sigmoidal
dependence of inhibition upon inhibitor concentration suggests that BocD has a cooperative or
two-state binding as described for another irreversible inhibitor in (Qiu, Chen et al. 2005). The
two-states may reflect different binding modes of BocD in the same site, or binding to the two
active sites in the caspase heterotetramer. The inhibition increased when the BocD was incubated
longer with the caspase-3 before the activity was assayed (Fig 2.2b). The time dependency
suggests that BocD acts as a slow binding inhibitor.
2.3.3. Overall Structures of Four Caspase-3 Complexes
Caspase-3 was crystallized in complex with three tetrapeptide aldehyde inhibitors, IEPD,
WEHD, and YVAD, as well as one modified monopeptide inhibitor BocD, in order to study the

42
binding of hydrophobic P4 residues. The crystallographic data and refinement statistics are
summarized in Table 2.1. The proteins crystallized in two space groups: primitive orthorhombic
space group P212121 and primitive monoclinic space group P21. The four structures were refined
to the resolutions of 1.9-2.6Å with R factors of 21.4-24.4%. All the four complexes consist of
two p17/p12 heterodimers in their asymmetric units. The main chain conformations of caspase-3
in the four complexes are essentially identical and they closely resemble our previously reported
structure of caspase-3/DEVD (2H5I) with overall rmsd of 0.41-0.49 Å for Cα atoms. Overall, the
side chain atoms share similar conformations since the average all atom rmsd for the four
structures is 0.7 Å, and the average for residues in the active site cavity is almost identical at 0.8
Å.
The three tetrapeptide inhibitors were bound in extended conformations in the S1-S4
substrate binding sites of caspase-3 (Fig. 2.3a). The 2Fo-Fc electron density map of inhibitor
YVAD is shown in Figure 2.3b. A thiohemiacetal bond was formed between the aldehyde group
(-CHO) of the inhibitor and the mercapto group (-SH) of the catalytic site Cys163. The main
chain atoms of all three inhibitors shared similar positions and their Cα atoms superimposed very
well with average rmsd of 0.27 Å for four Cα atoms. On the other hand, significant
conformational variations were observed when side chain atoms were compared. Compared with
the canonical inhibitor DEVD, the three weaker inhibitors differ mainly at P2 and P4 positions,
and the structural differences will be explained in the later sections.
Caspase-3 was crystallized with the inhibitor BocD in order to study the unliganded S4
pocket. BocD was observed in a unique mode of binding. The Fo-Fc map in the substrate
binding site clearly indicated that this inhibitor only occupied the S1 and S2 pockets of caspase-3
(Fig. 2.3c). A zwitterionic intermediate was formed between the fluoromethyl ketone (-FMK) on
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the inhibitor and the mercapto group (-SH) of Cys163. Although it has been claimed that this
inhibition could be reversed in certain conditions, such as high DTT (1,4-dithio-threitol)
(Ganesan, Mittl et al. 2006), this class of inhibitors is conventionally considered to be
irreversible caspase inhibitors in physiological conditions.
2.3.4. Inhibitor Interactions in the S1-S3 Subsites
The peptidic inhibitors formed a series of hydrogen bond and ionic interactions in the
caspase active site cavity, as shown in Figure 2.4. The interactions in each subsite are described
separately. Caspases are known to have a stringent requirement for aspartic acid at the P1
position of their substrates. In agreement, the P1 Asp of the three tetrapeptide inhibitors bound in
the S1 pocket in very similar conformations. The major interactions in S1 include both ionic
bonds and hydrogen bonds formed between P1 Asp and Arg64, Arg207, Gln161, and Ser205.
Although P1 Asp is critical for tight binding of peptides, its negative charge is undesirable in
potential drugs. The inhibitor BocD illustrates one way to improve cell permeability by
methylation of one side chain oxygen atom of the P1 Asp. The methyl-Asp occupied the S1
pocket of caspase-3 in a comparable conformation to the P1 Asp of the canonical inhibitor
DEVD (Fig. 2.4a) except that the methyl group extended into the pocket towards Gln161. The
neutralized P1 group formed single hydrogen bond interaction, instead of ionic interaction, with
the positively charged Arg64 and Arg207. The interaction with Gln161 was not observed in this
structure (Fig. 2.4d). From the protein perspective, the conformations of S1 residues were
conserved in all four complexes.
The S2 subsite is formed by three hydrophobic residues, Tyr204, Trp206, and Phe256. Its
plasticity was explored using the residues Pro and His, as well as the hydrophobic moiety Boc
(tert-butoxycarbonyl) in the new structures. In the structure of caspase-3/IEPD, the P2 Pro neatly
fitted into the S2 subsite. Although its side chain is smaller than Val in the canonical DEVD,
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three S2 residues shifted their side chains towards the P2 Pro reducing the size of the S2 pocket.
Consequently, proline has favorable van der Waals interactions with these three S2 residues (Fig.
2.5b). Compared with proline, histidine was not expected to be an attractive P2 residue due to its
bulkier side chain. In the structure of caspase-3/WEHD, however, the P2 histidine was
accommodated in the S2 pocket with its aromatic ring pointing into the solvent (Fig. 2.5c). All
the side chain carbon atoms formed van der Waals interactions with the three hydrophobic S2
residues. Compared with P2 Val of canonical DEVD, the Cα atom of His had moved a little
further from the S2 residues, which was likely due to the larger size of the His side chain. In the
caspase-3/BocD complex, the hydrophobic Boc group occupies the equivalent P2 position.
Unexpectedly, the electron density map clearly showed that the Boc group was directed out of
the S2 subsite, (Fig. 2.3c; 2.5d). Although the terminal carbon atoms of the Boc group had
interactions with Tyr204, the interactions with Trp206 and Phe256 were lost. This analysis
suggests that the S2 subsite of caspase-3 prefers small hydrophobic moieties like Val or Pro, and
the Boc group is too bulky for optimal fit.
The primary interactions in the S3 pocket are the main chain hydrogen bonds formed
between the P3 residue and Arg207. They are conserved independent of the type of amino acid at
P3. In these structures of caspase-3 with IEPD, WEHD, and YVAD, Glu and Val formed similar
main chain interactions in the S3 pocket as described in an earlier study (Fang, Boross et al.
2006). Therefore, P3 Val can be accommodated in the S3 subsite, although earlier binding
studies showed that caspase-3 preferred hydrophilic residues, with the highest affinity for P3 Glu
in peptides (Thornberry, Rano et al. 1997). The side chain of P3 Glu formed hydrogen bond
interactions with the side chain hydroxyls of Ser65 and Ser209 in caspase-3/WEHD, however,
the P3 Glu in IEPD only retained the interaction with Ser65 while the side chain of Ser209
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rotated to interact with its neighbor Lys210. A water mediated hydrogen bond was formed
between P3 Glu and Arg207 in both structures. In contrast, the side chain of P3 Glu in the
canonical inhibitor DEVD formed a direct hydrogen bond with Arg207 but had no hydrogen
bonds with Ser65 and Ser209 (Fig. 2.5e). These differences imply that the interactions of the P3
side chain depend on the type of amino acid at positions P2 and P4, however, further studies are
necessary to address this question.
2.3.5. S4 Subsite
In our previously reported structure of caspase-3/DEVD, the P4 Asp interacted with the
main chain atoms of Phe250 and Asn208 through its side chain oxygen atoms and main chain
amide group. Those polar interactions tightly anchored the P4 Asp in the S4 subsite. In contrast,
the three hydrophobic P4 residues in the new structures showed no direct hydrogen bonds with
S4 residues, except for the hydrogen bond between the amide of P4 Ile in IEPD and the carbonyl
oxygen of Phe250 (Fig. 2.4a). In caspase-3/YVAD a water mediated hydrogen bond interaction
was found between the side chain hydroxyl of P4 Tyr and the main chain atoms of Gln248.
Despite the paucity of polar interactions, the three P4 residues formed favorable hydrophobic
interactions in two separate regions of the S4 pocket. In the structure of caspase-3/IEPD, the side
chain of Ile was rotated slightly into the S4 subsite compared with the conformation of P4 Asp in
caspase-3/DEVD, and fitted in a non-polar pocket formed by the aromatic side chains of Trp206
and Trp214 (Fig. 2.5f). Similar favorable van der Waals interactions between P4 Ile and two Trp
residues were observed in the complex of caspase-7/IEPD (Agniswamy, Fang et al. 2007). Also,
the S4 subsite of initiator caspase-8 is formed by two aromatic residues, Trp420 and Tyr412,
consistent with the preference for Ile at P4 position. In the complex of caspase-3/YVAD, the P4
Tyr lay in the S4 pocket with its side chain hydroxyl directed out of the substrate binding groove.
The P4 Tyr formed favorable van der Waals bonds with Trp214 and Trp206 (Fig. 2.5g). The
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terminal acetyl oxygen of YVAD formed hydrogen bonds with the main chain and side chain of
Ser209, whereas, the acetyl group of IEPD formed a water-mediated interaction with the side
chain of Ser209, and these interactions also contribute to the binding affinity (Fig. 2.6).
In the complex of caspase-3/WEHD, the P4 Trp binds in the S4 subsite in a unique
manner. The entire side chain of Trp and the acetyl group were rotated by about 90° (Fig. 2.5h).
Consequently, the aromatic ring of P4 Trp interacted with the hydrophobic side chains of Phe250
and Phe252 that were proposed to form the S5 pocket of caspase-3 (Fang, Boross et al. 2006).
Because of the rotation, the acetyl oxygen formed a hydrogen bond with the main chain amide of
Phe250 instead of the interaction with Ser209 seen in the other complexes (Fig. 2.4b). Moreover,
the interaction of P4 Trp with Phe250 and Phe252 in the S5 subsite appeared to trigger a closure
of about 0.9 Å of the loops 1 and 4, similar to the conformational change and induced fit
mechanism proposed in our previous studies of caspase-3 with P5-containing pentapeptides
(Fang, Boross et al. 2006).
Although BocD does not possess a P4 residue, a glycerol molecule was found in the S4
subsite in the crystal structure of caspase-3/BocD. The glycerol molecule was positioned to form
two hydrogen bonds between glycerol oxygen O1 and O2 and the side chain nitrogen of Trp214
as well as the amide group of Phe250, respectively (Fig. 2.5i). The binding of glycerol reflects
the polar nature of the S4 subsite. In the absence of P4-containing ligand, S4 is highly accessible
for water and other polar solvent molecules.
Overall, the structures showed that the different P4 residues can bind with small
conformational changes in the caspase-3 residues, similar to the observations for caspase-7
(Agniswamy, Fang et al. 2007). The divergent binding modes of the various P4 residues imply
that, although polar residues bind favorably in the S4 subsite, non-polar residues can be
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accommodated without triggering substantial conformational changes. Two distinct hydrophobic
pockets provide interactions with hydrophobic P4 in the S4 region. Trp206 and Trp214 form an
inner subsite, which is suitable for smaller non-polar side chains while Phe250 and Phe252 form
an outer pocket, which is suitable for larger hydrophobic P4 side chains like Trp or, alternatively,
P5 residues like Val or Leu. The binding modes of P4 Trp and P4 Tyr in YVAD and WEDH,
respectively, illustrate the two distinct pockets (Fig. 2.6). This structural analysis explains why
some natural substrates of caspase-3 have hydrophobic P4 resides, such as Ile and Leu in CREB
and DCC, respectively (Backes, Kuentzer et al. 2005).
2.3.6. Correlation of Structural Interactions with Inhibition
The three substrate analog inhibitors share the same P1 Asp residue. They exhibit
comparable conformations for P1 and have similar interactions with S1 residues. In the next
subsite, all three different P2 residues exhibited favorable van der Waals interactions with S2
residues. Therefore, the variations of P3 and P4 are the primary factors influencing inhibitory
potency. The three tetrapeptide inhibitors showed weak inhibition compared with canonical
inhibitor DEVD (Table 2.2). IEPD is the strongest among three with a Ki value of thousand
times higher than for DEVD. The weakest inhibitor YVAD is ten-fold weaker than IEPD.
Structural analysis suggests that Ile is the most favorable of the three P4 residues because it
preserves a main chain hydrogen bond interaction with Phe250. Tyr is the next most favorable
since its side chain has a water mediated hydrogen bond with Gln248. The Trp is ranked last
because of two reasons. First, it has no polar interactions with S4 residues unlike the other two
residues. Second, the binding to the S5 pocket requires rotation of its entire bulky side chain. At
the P3 position, Glu is clearly more favorable than Val in the S3 subsite. The positively charged
Arg207 and hydrophilic Ser65 firmly anchored the negatively charged Glu in the S3 pocket. On
the contrary, the Val side chain has no favorable interaction with S3 residues. Thus, the variation
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of P3 is the primary reason for the inhibitory differences of the three inhibitors. Overall, the
substitution of P4 Asp with hydrophobic residues resulted in dramatically reduced inhibitory
potency. IEPD was the best because P4 Ile has a better fit in S4 than other two and P3 Glu is
favorable. YVAD showed the weakest inhibition mainly because of the mismatch of P3 Val in
the S3 subsite. WEHD had the least favorable P4 residue, however, the favorable P3 Glu
interaction still made a stronger inhibitor than YVAD. Moreover, the side chain of P3 Glu in
WEHD formed one more hydrogen bond with Ser209 relative to P3 Glu in IEPD. This analysis
illustrates the effects of combining sequence variations at the P4 and P3 positions, which is
expected to influence the efficiency of hydrolysis of proteins with different sequences at their
cleavage sites.
From the viewpoint of numbers of favorable interactions with caspase-3, BocD should
exhibit the lowest binding affinity as reflected in our inhibition assay. The methylated P1 Asp is
uncharged and less favorable than the negatively charged Asp for binding the positively charged
S1 pocket. The consequence is that a higher concentration of the inhibitor needs to be
accumulated in order to effectively block the active site of the enzyme. Hence, the poor
performance of BocD was observed in the low concentration range. In the higher concentration
range, BocD was a stronger inhibitor than WEHD and YVAD because it can irreversibly
inactivate caspase-3.
2.3.7. Predicted Binding Of Diverse P4 Residues
The analysis of mode of binding and inhibition of P4 residues was extended to all 20
amino acids by molecular modeling. 20 residues at the P4 position in peptide inhibitor XEVD
were modeled in their complexes with caspase-3. The program AMMP (Harrison 1993) was used
for modeling with the crystal structure of caspase-3/DEVD (2H5I) comprising one inhibitor
bound to one large and one small caspase subunit as the initial template. The structural
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interactions and the interaction energies were predicted for the peptides in the molecular models
of caspase-3/XEVD. Importantly, the predicted conformations of the P4 Ile, Trp and Tyr in the
inhibitor XEVD closely resemble those observed in our crystal structures (Fig. 2.7).
The accuracy of the energy calculation was evaluated using the seven commercial
caspase tetrapeptide inhibitors with Ki values determined in our caspase-3 activity assay (Table
2.2). To our knowledge, this is the most complete set of aldehyde tetrapeptide inhibitors of
caspase-3 at present. As shown in the Fig 2.7a, the observed free energies (ΔG) derived from
experimental Ki values for the seven inhibitors showed excellent correlation (R of 0.83) with the
calculated interaction energies for the models. The calculated interaction energy is an estimate of
the internal energy ΔU, which is assumed to dominate the changes in free energy. In these
calculations on a single configuration the effects of entropy and energy of solvation are assumed
to be small or similar for the series of inhibitors. Therefore, the estimate for ΔU can be used to
estimate trends in binding free energy ΔG for different peptides. The high correlation indicates
that these structural models and energy calculations are reliable.
In order to estimate relative binding affinities for all 20 P4 residues in the peptide XEVD,
structural models were also made with Asp, Ile, Trp, and Tyr in the P4 position using the same
procedure. The predicted Ki values of inhibitors XEVD, which were derived from mapping the
calculated interaction energies onto the regression line in Fig 2.8a, are shown in Fig 2.8b. The P4
Asp showed the highest affinity in the prediction, in agreement with experimental results. The
inhibitor with P4 Glu was predicted to be the second strongest one. Arg and Asn were predicted
to be the next best at P4 in this tetrapeptide, although Lys and His were among the weaker
inhibitors. Among the hydrophobic P4 residues, aliphatic residues were predicted to show better
binding than aromatic residues. These results are consistent with the previous experimental
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analysis of caspase-3 substrate preference (Thornberry, Rano et al. 1997). The predicted trends in
binding affinity showed general agreement with the residue ranking in our analysis of natural
substrates (Fig 2.1), although deviations appeared for some residues such as Arg and Asn. The
predictions for relative inhibition from the energy calculations assume that changes in entropy
and solvation energy are negligible. Also, the binding affinity depends on the entire substrate and
the models used tetrapeptides with optimal residues at P1 to P3 instead of the full-length protein
substrates with a variety of residues at these positions. Therefore, experimental data for proteins
with different cleavage site sequences are required in order to more fully understand the substrate
specificity of caspase-3.
The model complexes were analyzed for the binding mode of the different P4 residues
(Fig. 2.9). Most of the sixteen residues showed similar conformations with interactions
depending on the type of side chain at P4. The eight polar P4 residues Arg, Lys, Glu, Asn, Gln,
His, Ser and Thr were predicted to form at least one side chain hydrogen bond interaction with
caspase residues. Most of them interacted with the main chain atoms of Phe250 (Fig. 2.9). The
P4 Arg and Lys were predicted to form hydrogen bonds with the main chain of Glu248 and the
side chain of Asn208, and P4 His formed a hydrogen bond with Ser209. On the other hand, the
hydrophobic residues Pro, Ala, Cys, Val, Leu, Met and Phe interacted with S4 subsite through
van der Waals interactions with distance cutoff of 3.8-4.2 Å. All of these residues interacted with
Trp206. In addition, P4 Leu, Met and Phe interacted with Phe250, and P4 Leu also interacted
with Trp214. Glycine is not shown in the figure since it does not have a side chain. Most acetyl
group on the inhibitors formed hydrogen bond interactions with Ser209, as observed for crystal
structures of caspase-3/IEPD and YVAD (Fig. 2.4). An exception was observed in the model
with P4 Phe, where the acetyl interacted with Asn208 and Trp214 instead. This change was
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because the side chain of P4 Phe had rotated towards Phe250 and Phe252 similar to the rotated
conformation seen for P4 Trp in the crystal structure of caspase-3/WEHD (Fig. 2.6).
Independent of the predicted binding affinities, most P4 residues were accommodated
without greatly changing the conformation of the S4 pocket. His and Phe were only two P4
residues that showed considerable conformational change when bound to the enzyme, which is
consistent with their higher estimated Ki compared with others. Our results imply that the S4
subsite is capable of accommodating various P4 residues. Hydrophilic P4 residues are predicted
to interact with F250 and N208, whereas hydrophobic P4 residues are predicted to interact with
W206 and F250. According to the calculated interaction energy, most substitutions of P4
resulted in a hundred fold decrease in the binding potency compared with inhibitor DEVD. The
binding affinity, however, will also depend on the residues present at other positions, such as P3.
Further analysis will be needed to explore the effect of variations at other positions in the
cleavage sites. Moreover, a substrate protein with a significantly lower binding affinity can still
effectively bind to caspase-3 and be hydrolyzed in physiological conditions. This analysis
explains why a large number of non-canonical substrate sequences have been found.
2.4. Discussion
Since the original work of Thornberry and Talanian (Talanian, Quinlan et al. 1997;
Thornberry, Rano et al. 1997), the idea of consensus recognition sequences was established as
the basis of the current substrate and inhibitor research of caspases. DxxD was considered the
classic substrate recognition motif for caspase-3 and -7 from studies of short peptides. This
information, however, is misleading in searching for cellular caspase substrates because a
substrate protein does not have to bind with the highest affinity. Numerous natural substrates of
caspases have been discovered by in vitro kinetic studies, in vivo cleavage studies, and
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mutagenesis studies. For example, in one recent study, 27 out of 59 natural caspase-3 substrates
do not have Asp at P4 in their cleavage sites (Backes, Kuentzer et al. 2005). In fact, 10 of those
substrates possess hydrophobic P4 residues. We have extended the statistics on natural substrates
of caspase-3 and found that 45% of 182 reported natural caspase-3 substrates possess residues
other than Asp at P4, and over a third of them are non-polar residues. It challenges the older
understanding of substrate recognition of caspase-3 from earlier in vitro kinetic studies on
peptides. Crystal structures of caspase-substrate complexes can shed light on this problem by
providing direct evidence of whether a putative substrate can bind and how it binds.
Our structures with three substrate analog inhibitors have demonstrated the binding
modes of non classical residues from P2 to P4 positions. The hydrophobic S2 subsite of caspase3 was suggested to preferentially recognize aliphatic residues. Nevertheless, some natural
caspase-3

substrates have aromatic residues at P2, such

as PAPD

in

CAMK4

(calcium/calmodulin dependent protein kinase IV) and DRHD in NFKBIA (nuclear factor of
Kappa light peptide gene enhancer in B-cells inhibitor, alpha) (Backes, Kuentzer et al. 2005). In
our structures, the aromatic side chain of His and hydrophobic Pro were both accommodated in
the S2 subsite. This observation is consistent with a previous screening study where proline was
found to be one of the best P2 residues (Lien, Pastor et al. 2004). Furthermore, the pyrrolidine
ring has been successfully utilized at P2 in the development of caspase-3/7 inhibitors, such as the
isatin sulfonamide inhibitors (Lee, Long et al. 2000). Clearly, the S2 subsite of caspase-3 can
accommodate both aliphatic residues and aromatic residues. At the P3 position, our analysis
confirmed previous studies that various residues can bind in S3, among which Glu is the best.
At the P4 position, the three groups of caspases exhibit distinct preferences. Initiator
caspases prefer Leu/Ile/Val, inflammatory caspases prefer Trp, while executioner caspases
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demonstrate a strong preference for Asp at P4 position and any substitution resulted in thousandfold difference in the binding affinity. This characterization was challenged by several previous
studies where caspase-8 was shown to tolerate P4 Asp (Blanchard, Donepudi et al. 2000) and
caspase-7 was shown to accommodate hydrophobic P4 residues such as Trp (Agniswamy, Fang
et al. 2007). The cleavage sites of many caspase-3 natural substrates, such as YVPD in CDC2L1
(cell division cycle 2 like 1 protein) and ILND in CREB (cAMP response element-binding
protein) (Backes, Kuentzer et al. 2005) underlined the natural ability of caspase-3 to bind diverse
P4 residues in vivo. Several polar residues have showed tight interactions with S4 in our
predictions, including Asp, Glu, Asn and Ser. Although hydrophobic residues showed weaker
interactions in the S4 subsite, most of them can be accommodated in favorable conformations in
our models as well as in the crystal structures. Our previous studies revealed that the S4 subsite
of caspase-7 has dual functionality with a hydrophilic area and a hydrophobic area (Agniswamy,
Fang et al. 2007). In the current study, the same feature was found in the S4 subsite of caspase-3.
The side chain of P4 Ile in IEPD and P4 Tyr in YVAD interacted with a hydrophobic pocket
formed by Trp206 and Trp214 deep inside the S4 subsite. In contrast, the side chain of P4 Trp in
WEHD extended out of the S4 subsite and made contact with the reported hydrophobic S5
residues (Fang, Boross et al. 2006). The physiological function of hydrophobic S5 is reflected in
the crystal structure of XIAP bound with caspase-3 (Riedl, Renatus et al. 2001), where Ile149
and Ile153 of XIAP interacted with S5 residues. In the absence of structural information for
natural caspase substrates, the roles of Trp206 and Trp214 in the S4 subsite were not understood
before. Nevertheless, their ability to interact with non-polar residues was revealed in this study.
Van der Waals interactions between hydrophobic P4 residues and Trp206 were also conserved in
our structural models. This analysis supports the existence of the inner non-polar pocket of the
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S4 subsite. The discovery of dual functionality of the S4 subsite and the binding modes of
diverse P4 residues provides the structural basis for binding of non-polar residues in S4 subsite.
Small aliphatic non-polar residues such as Ala, Val, and Leu are better accommodated than
aromatic residues in the inner pocket of S4, which may explain the relative frequency in the
caspase cleavage sites. However, the P4 preferences will likely differ in the context of a fulllength protein substrate rather than a short peptide. Protein substrates may form additional
interactions at exosites, as described for caspase-7 (Agniswamy, Fang et al. 2007). Although the
mechanism is not fully understood, it is clear that some non-polar P4 residues such as Ala, Val,
and Leu, must be considered when searching for potential caspase-3 substrates.
Last but not least, the information on binding of non-polar P4 residues to caspase-3 can
facilitate the development of new inhibitors and drugs. Current drug design for caspase-3 is
mostly limited to the P1, P2 and P3 positions. Introduction of a hydrophobic P4 moiety would
not only facilitate the binding, but also improve the cell permeability. Compound IDN-6556 is
one such example (Pockros, Schiff et al. 2007). Although the structure of its complex with
caspase is not available, the aromatic moiety at its N terminus is likely to bind in the S4 of
caspase-3 (Irene T. Weber 2008). This oxamyl peptide compound showed inhibition of all
caspases and is currently under phase II clinical trials in patients with liver transplants (BaskinBey, Washburn et al. 2007). The results from this study should be considered in the future
development of therapeutic compounds.
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Table 2.1. Crystallographic data collection and refinement statistics
Caspase3/

Caspase3/

Caspase3/

Caspase3/

Ac-YVAD- Ac-IEPDCho
Cho

Ac-WEHDCho

Ac-D(Me)Fmk

Space group

P21

P212121

P212121

P21

a (Å)

50.4

68.2

69.1

50.4

b (Å)

70.3

88.3

88.2

69.7

c (Å)

93.4

96.9

96.6

93.4

β(°)

102.4

90

90

102

Resolution range

50-1.9

50-2.2

50-2.6

50-2.2

Completenessa

85.7(52.0)

99.7(99.3)

99.7(99.7)

95.1(75.0)

<I/σ(I)>

13.18(3.0)

21.3(10.7)

12.3(7.0)

11.9(2.8)

Rsym (%)b

7.3(21.4)

7.6(17.9)

11.2(33.1)

11(30.5)

Resolution range

10-1.9

10-2.2

10-2.6

10-2.2

Rcryst (%)c

21.6

24.4

23.6

21.4

Rfree (%)d

24.8

28.8

29.0

25.3

Average B factor (Å2)

25.3

25.5

31.2

20.7

No. protein atoms

3908

3786

3776

3774

No. water atoms

299

134

49

181

Bond length rmsd (Å)

0.007

0.007

0.007

0.007

Angles rmsd (°)

1.3

1.3

1.3

1.3

Refinement statistics

a

Values in parentheses are given for the highest resolution shell. bRsym = Σhkl|Ihkl 〈Ihkl〉|/ΣhklIhkl. cR = Σ|Fobs-Fcal|/ΣFobs. dRfree = Σtest(|Fobs|-|Fcal|)2/Σtest|Fobs|2.
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Table 2.2. Inhibition constants
Inhibitor

Ki (nM)

Ac-DEVD-Cho

1.2 ± 0.05

Ac-DQMD-Cho

11.0 ± 0.5

Ac-DMQD-Cho

12.0 ± 0.5

Ac-IEPD-Cho

170 ± 7

Ac-ESMD-Cho

1200 ± 48

Ac-WEHD-Cho

4700 ± 190

Ac-YVAD-Cho

10200 ± 410

Caspase-3 was preincubated with its inhibitors in reaction buffer (50 mM HEPES, 100 mM
NaCl, 0.1% CHAPS, 10% glycerol, 1mM EDTA and 10 mM dithiothreitol, pH 7.5) at room
temperature for 15 mins. Substrate was then added and reaction product p-nitroanilide was
measured at a wavelength of 405 nm. The inhibition constants were determined by using the
equation: Ki = (IC50-0.5[E])/(1+[S]/Km), where [E], [S] and IC50, respectively, correspond to
active enzyme concentration, substrate concentration, and the inhibitor concentration needed to
suppress half enzyme activity. The enzyme concentration was determined by active site
titration.
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Figure 2.1. The occurrence of different amino acids at P4 in the cleavage sites of natural
substrates of caspase-3. Different residues are represented in different colors.
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Figure 2.2. Inhibition characterization of caspase-3 inhibitors. (a) Inhibition profiles of caspase-3 inhibitors IEPD (▲) and BocD
(●). The fractional inhibition is calculated as V/V0×100%, where V and V0 refer to velocities with and without inhibitor respectively.
Caspase-3 was preincubated with inhibitors in reaction buffer (50 mM HEPES, 100 mM NaCl, 0.1% CHAPS, 10% glycerol, 1mM
EDTA and 10 mM dithiothreitol, pH 7.5) at room temperature for 30 mins. Inhibition profile of IEPD was fitted using hyperbola
equation: Inh=Inhmax[I]/(Kd+[I]), while inhibition profile of IEPD was fitted using sigmoidal equation: Inh=Inhmin+(InhmaxInhmin)/(1+10^(logEC50-[I])). Inh, [I], and EC50 refer to fractional inhibition, inhibitor concentration, and the inhibitor concentration
provides the halfway inhibition. The sigmoidal inhibition profile of BocD suggests a cooperative binding mechanism. BocD may bind
to an allosteric site on caspase-3, which in turn facilitates the binding of BocD in the active site of the protein. (b) Time dependence of
the initial velocity was measured using 300 nM of caspase-3 and 2µM of BocD after preincubation for 0 to 60 mins. Because time
dependence inhibition profiles of irreversible inhibitors typically follow exponential decay, data in the graph was fitted into the
exponential decay curve defined by equation: V=Vmin+a*exp(-bt), where V and t refer to initial reaction velocity and time,
respectively.
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Figure 2.3. Binding conformations of inhibitors. (a) Superposition of four inhibitors in the
substrate binding site of caspase-3. Inhibitors IEPD (blue), WEHD (magenta), YVAD (yellow),
and BocD (green) are shown in stick representation. The binding surface of S1-S4 subsites is
shown in pale blue. (b) 2Fo-Fc electron density map of inhibitor YVAD contoured at a level of
1.4σ. (c) Fo-Fc electron density map of inhibitor BocD in the complex of caspase-3/BocD. The
map was contoured at a level of 1.4σ. The inhibitor covalently binds to active site Cys163. The
backbone of loops forming the substrate binding site is illustrated as ribbons.
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Figure 2.4. Schematic representation of hydrogen bond and ionic interactions between caspase-3 and the inhibitors. (a) IEPD,
(b) WEHD, (c) YVAD, and (d) BocD. The protein residues are in blue and inhibitors are in black. Interactions are indicated in dash
lines.
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Figure 2.5. Comparison between subsites in four new complexes (color) and published
structure of caspase-3/DEVD (grey) (2H5I). (a) The methylated P1 Asp of BocD and S1
residues. (b)-(d) P2 residues Pro, His, and Boc moiety, respectively are shown in S2 subsite. (e)
P3 Glu in structure caspase-3/IEPD (purple) and caspase-3/WEHD (magenta). (f)-(h) The
binding of P4 Ile, Tyr, and Trp, respectively, in S4 subsite. (i) The unbound S4 has glycerol in
the BocD complex. Hydrogen bonds are represented by dashed lines. The boxed caspase-3
residues form hydrogen bonds or hydrophobic interactions with inhibitors.
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Figure 2.6. P4 binding site on caspase-3. P4 residues Ile (green), Tyr (cyan), and Trp (yellow)
can bind in either the S5 pocket formed by Phe250 and 252 (orange) or another hydrophobic
pocket formed by Trp206 and 214 (orange).
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Figure 2.7. Superposition of inhibitors in the crystal structures (green) and structural
models (purple). (a) IEPD/IEVD (b) YVAD/YEVD (c) WEHD/WEVD
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Figure 2.8. Predicted binding affinities for diverse P4 residues. (a) The correlation between
experimental binding energies and calculated interaction energies. (b) Predicted Ki values of
inhibitors Ac-XEVD-Cho.
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Figure 2.9. Predicted binding conformations of fifteen different P4 residues in caspase-3/XEVD. The P4 residue is located in the
center in the stick representation, while caspase residues are shown as lines. The letter in the top left corner is the name of the P4
amino acid. Hydrogen bond interactions are indicated by dashed lines. Caspase residues involved in polar interactions are labeled in
black, while those involved in van der Waals interactions are labeled in blue.
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3. STRUCTURAL AND KINETIC ANALYSIS OF CASPASE-3 REVEALS ROLE FOR
S5 BINDING POCKET IN SUBSTRATE RECOGNITION
3.1. Introduction
Caspases promote apoptosis by proteolytic cleavage of a number of downstream protein
substrates(Alnemri, Livingston et al. 1996). Caspase activity is associated with a variety of
diseases including neurodegenerative disorders, ischemic injury and cancers (Thompson 1995).
Caspase-3 mediated apoptosis has a major role in neurodegenerative diseases (CharriautMarlangue 2004). Caspase-3 is activated in spinal cord injury and Alzheimer’s disease, where it
can cleave the amyloid-beta precursor protein and influence apoptosis of neurons (Kim,
Pettingell et al. 1997; Gervais, Xu et al. 1999). Several peptidomimetic and nonpeptide caspase-3
inhibitors have been found to inhibit apoptosis (Lee, Long et al. 2000; Micale, Vairagoundar et al.
2004). Inhibitors of caspase-3 were shown to prevent neuronal loss in mouse models (Takuma,
Tomiyama et al. 2004). On the other hand, the deficiency or suppression of caspases is a factor in
the development of cancer and autoimmune diseases (Thompson 1995; Soengas, Alarcon et al.
1999), and tumor specific gene therapy based on caspase-3 has been explored (Yang, Cao et al.
2004). Moreover, abnormal heart development was found in knockout mice without caspase-3
and -7 (Lakhani, Masud et al. 2006).

Consequently, caspase-3 is required for normal

development and control cell death in many diseases (Philchenkov 2004).
Information on the molecular structure and substrate specificity of caspase-3 is valuable
for understanding the development of disease and for the design of new therapies. The crystal
structures are known for the catalytic domain of caspase-3, both unliganded and in complex with
different peptidic, non-peptidic, or protein inhibitors (Fuentes-Prior and Salvesen 2004; Salvesen
and Abrams 2004). The catalytic domain comprises a small (12 kD) and large (17 kD) subunit
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arising from cleavage of the procaspase-3. The peptide substrates or inhibitors consisting of
residues P4-P1’, where the scissile peptide bond is between P1 and P1’, are bound in pockets S4S1’ formed by the caspase. Generally, peptidic inhibitors contain aldehydes (Cho) or
fluororometyhlketones (fmk) that form a covalent link with the catalytic Cys 163, as shown in
the caspase-3 complexes with peptide inhibitors Ac-DVAD-fmk (Mittl, Di Marco et al. 1997)
and Ac-DEVD-Cho (Rotonda, Nicholson et al. 1996) (where Ac is the acetyl group).
All caspases have a stringent specificity for Asp at P1 in the substrate. Caspase-3 and –7
are effector caspases that recognize the canonical peptide sequence of DEVD and are involved in
similar signaling pathways. In caspase-3 the P1 Asp is bound in a deep basic pocket formed by
the conserved residues Arg 64, Arg 207 and Gln 161, and a peptide with Glu at P1 instead of
Asp was hydrolyzed at a 20,000-fold lower kcat/Km (Stennicke, Renatus et al. 2000). Caspase-3
was shown to preferentially cleave the peptide bond after the optimal sequence of DE(V/I)D in a
combinatorial peptide library (Thornberry, Rano et al. 1997). Other studies using peptides with
substitutions at different positions suggested the preferred peptide sequence of DE(M/L)D-(S/G)
(Talanian, Quinlan et al. 1997; Stennicke, Renatus et al. 2000). However, peptide library
searches with a substrate-phage selected DLVD with 170% faster hydrolysis than the canonical
DEVD peptide(Lien, Pastor et al. 2004). These results suggest that the substrate preferences for
P2 and P3 are not fully understood. Although most caspase family members have been shown to
recognize a tetrapeptide of P4-P1, the P5 position was determined to be essential for the substrate
selectivity of caspase-2 (Talanian, Quinlan et al. 1997; Schweizer, Briand et al. 2003). Few
studies, however, have been performed to investigate the P5 position in other caspases. Clearly,
the substrate or inhibitor specificities of caspases are not fully understood.
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In order to improve our knowledge of the molecular basis for substrate specificity the
crystal structures were determined of complexes of recombinant human caspase-3 with the
peptide analogs Ac-DEVD-Cho, Ac-DMQD-Cho and Ac-VDVAD-Cho. The complex with AcDEVD was obtained at the significantly higher resolution of 1.70 Å compared to 2.5 Å for the
previously reported structure (Rotonda, Nicholson et al. 1996). These complexes explore the
specificity for positions P2 and P3 in the peptide substrates, and examine the effect of adding the
P5 residue. The analysis of these new structures with peptide analog inhibitors will help in the
design of new caspase-3 inhibitors as potential therapeutic agents for neurodegenerative diseases.
3.2. Materials and Methods
3.2.1. Protein Expression and Purification
The cloned full length human caspase-3 cDNA was expressed as previously described
(Stennicke and Salvesen 1997). Cells were harvested and resuspended in lysis buffer (20 mM
Tris-HCl, 5 mM imidazole, 25 mM NaCl, 5 mM dithiothreitol, 0.1 mg/ml lysozyme and 0.1%
Triton X-100, pH 7.5). Cell crude extract, obtained by sonication and centrifugation, was filtered
with 0.2μm filters and loaded onto the nickel affinity column (HisTrap™ HP, Amersham, NJ).
Caspase-3 was eluted by a gradient of 20-1000 mM imidazole. Imidazole in the protein solution
was subsequently removed by dialysis against 25 mM Tris-HCl, 20 mM NaCl, 10mM
dithiothreitol, pH 7.5. The partially purified caspase-3 was then loaded onto the anion exchange
column (High Q Cartridge, Bio-Rad, CA) and eluted by 20-1000 mM NaCl gradient. Salt
concentration was reduced to 20mM by buffer exchange using ultrafiltration. Further purification
was performed using a gel-filtration column (Superdex 75, Amersham, NJ) with the buffer 20
mM Tris-HCl, 20 mM NaCl, 10 mM dithiothreitol, pH 7.5. Finally, caspase-3 was concentrated
to 4mg/ml and stored at -80°C. The purity was determined to be over 99% by SDS-PAGE.
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3.2.2. Enzyme Kinetic Assays
Caspase-3 activity was determined using the colorimetric caspase-3 substrate Ac-DEVDpNA (Biomol, PA), where Ac is the acetyl group and pNA is p-nitroanilide. Caspase-3 was
preincubated in reaction buffer (50 mM HEPES, 100 mM NaCl, 0.1% CHAPS, 10% glycerol,
1mM EDTA and 10 mM dithiothreitol, pH 7.5) at room temperature for 5 mins prior to the
addition of substrate at various concentrations. p-nitroanilide released by enzyme cleavage was
measured at a wavelength of 405 nm using a Polarstar Optima microplate reader (BMG
Labtechnologies, NC). SigmaPlot 9.0 (SPSS Inc. IL) was used to obtain the Km and Vmax values
by fitting reaction velocities as described (Howard, Kostura et al. 1991). The catalytic constants
kcat of three caspase-3 substrates: Ac-DVAD-pNA (GenScript, NJ), Ac-VDVAD-pNA (Axxora,
CA) and Ac-LDVAD-pNA (GenScript, NJ) were determined by using the equation kcat=Vmax/[E],
where [E] values were measured by active site titration during Ki determination as described
below.
Caspase-3 substrate analog inhibitors Ac-DEVD-Cho (Biomol, PA), Ac-DMQD-Cho
(Calbiochem, CA), and Ac-VDVAD-Cho (Axxora, CA) bind to caspase-3 through thioether
bonds between the aldehyde (–CHO) group of the inhibitor and the mercapto (–SH) group of Cys
163 on the protein. According to the vendor instructions, the binding of these inhibitors is
reversible although it is strong. Therefore, they were treated as reversible tight binding inhibitors.
For the measurement of inhibition constant Ki, caspase-3 was preincubated with its substrate
analog inhibitors in reaction buffer at room temperature for 30 mins. Then, substrate was added
and reaction velocity was calculated according to substrate cleavage. The inhibition constants of
each inhibitor were determined by a dose-response curve described by the equation: Ki = (IC500.5[E])/(1+[S]/Km), where [E], [S] and IC50, respectively, correspond to active enzyme
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concentration, substrate concentration and the inhibitor concentration needed to suppress half
enzyme activity(Maibaum and Rich 1988).
3.2.3. Crystallographic Analysis
The inhibitors were dissolved in dimethylsulfoxide. Caspase-3 was incubated at room
temperature with the inhibitor at 20-fold molar excess. Crystallization was performed by the
hanging-drop vapor diffusion method. 1 µl of protein solution (4 mg/ml) was mixed with an
equal volume of 100 mM sodium citrate, 5% glycerol, 10 mM dithiothreitol, and 14-18%
PEG6000, pH 6.5. Crystals grew within 24 hrs at room temperature. The crystals were frozen in
liquid nitrogen with 15% glycerol as a cryoprotectant. X-ray diffraction data were collected on
the SER-CAT beamline at the Advanced Photon Source, Argonne National Laboratory.
The diffraction data were processed with HKL2000 (Otwinowski 1997). The structures
were solved by molecular replacement with the program AmoRe (Navaza 1994). The caspase-3
structure (1NME) (Erlanson, Lam et al. 2003) in the space group I222 was used as the initial
model for caspase-3/DEVD, while the structure 1CP3 (Mittl, Di Marco et al. 1997) was used as
the initial model for the two complexes in the P21 space group. The structures of caspase3/DEVD and caspase-3/DMQD were refined using the program SHELX97 (Sheldrick 1997) and
caspase-3/VDVAD was refined using CNS (Brunger, Adams et al. 1998) due to the lower
resolution. The molecular graphics program O 8.0 (Jones, Zou et al. 1991) was used to display
the electron density map and to refit structures. The initial inhibitor structures were generated by
energy minimization using AMMP (Harrison 1993). Water molecules and alternate
conformations of caspase-3 residues were modeled where observed in the election density maps.
Structural figures were made by Weblab viewer pro (Accelrys Inc., MA) and images of electron
density map were obtained using Molscript (Esnouf 1997; Esnouf 1999).
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3.2.4. Protein Data Bank Accession Codes
The crystal structures have been deposited in the RCSB Protein Data Bank with
accession codes 2H5I for caspase-3/DEVD, 2H5J for caspase-3/DMQD, and 2H65 for caspase3/VDVAD.
3.3. Results and Discussion
3.3.1. Crystal Structures
The crystal structures of caspase-3 were determined in the complexes with the three
substrate analog inhibitors Ac-DEVD-Cho, Ac-DMQD-Cho and Ac-VDVAD-Cho. The
crystallographic statistics are summarized in Table 3.1. The crystal structures were refined to the
resolutions of 1.7-2.3 Å and R-factors of 19.4-22.7. The structures of caspase-3/DMQD and
caspase-3/VDVAD have not been reported previously, while our structure of caspase-3/DEVD
was determined at a significantly higher resolution of 1.7 Å compared to 2.5 Å for the reported
structure of 1PAU (Rotonda, Nicholson et al. 1996). The mature caspase-3 consists of the p17
and p12 subunits derived from processing of the procaspase-3. The crystal structure of caspase3/DEVD has the p17/p12 heterodimer consisting of residues 29-174 and 185-277 in the
asymmetric unit of the I222 space group. Residues 175 in p17 and 176-184 in p12 were not
visible due to the weak electron density in the terminal regions. The complexes of caspase3/DMQD and caspase-3/VDVAD were crystallized in the P21 space group with two
heterodimers (p17/p12)2 (residues 34-174 and 186-277 for each heterodimer) in the asymmetric
unit (Fig 3.1). The terminal residues (29-33 and 175 in p17; 176-185 in p12) were not visible in
the electron density map.
The three caspase-3 structures are closely similar overall, with RMS deviations of 0.350.60 Å for Cα atoms although they were obtained in two different space groups. The major
differences, with RMS deviations on Cα atoms of greater than 1.0 Å, were in the loop1 (residues
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56-61) and loop4 (residues 251-254). In addition, the residues 29-33 at the N-terminus of the p17
subunit have visible electron density only in the structure of caspase-3/DEVD in the space group
I222. The p17 N-terminal region extends out of the p12/p17 heterodimer and interacts with the
C-terminal region of the p12 subunit of a symmetry related molecule. Hydrogen bond
interactions are formed between two symmetry related molecules: the main chain amide and
carbonyl oxygen of His277 interact with the carbonyl oxygen of Ile31 and the amide of Leu33,
respectively. In the structures of caspase-3/DMQD and caspase-3/VDVAD in space group P21,
no ordered density was observed for residues 29-33 and the p17 N-terminal region has no
contacts with nearby symmetry related molecules. Self processing is unlikely since the peptide
sequence of residues 30-33 GISL is not a site for self-cleavage of caspase-3 (Stennicke and
Salvesen 1997). Therefore, the conformation of p17 N-terminus is more flexible in the structure
in the space group P21.
Most of the residues in the active site had very similar positions in all three complexes.
The exception was the side chain of His 121, which is located beside the catalytic Cys 163 at the
bottom of the active site groove. In the structure of caspase-3/DEVD, the imidazole group of His
121 is directed away from the catalytic Cys 163 and into the substrate binding groove. In the
other two structures, the side chain of His 121 has different conformations in the two
heterodimers: one resembles that in caspase-3/DEVD, and the other is rotated so that the
imidazole group is closer to Cys 163 (Fig 3.2). This conformational change was not observed in
the previous caspase-3 structures (Rotonda, Nicholson et al. 1996; Mittl, Di Marco et al. 1997);
and it suggests that the side chain of His121 can approach Cys 163 to participate in the catalytic
reaction, and then move away after the cleavage has occurred to facilitate release of the reaction
products.
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3.3.2. Caspase-3 Interactions with Peptide Analogs
All the amino acids in the peptide analogs were clearly visible in the three structures. The
electron density map for the inhibitor in the caspase-3/DEVD structure is shown in Figure 3.3a.
The substrate analogs bind with thioether bonds between the aldehyde group (–CHO) and the
mercapto group (–SH) of Cys 163 of the caspase-3. The three inhibitors bind in the β-strand
conformation with almost identical overall conformation and atomic positions (Figure 3.3b).
Their Cα atoms (P1-P4) have small RMS deviations from 0.09Å to 0.3Å. The side chain atoms
of aspartates at P1 and P4 also have very similar positions. This rigid conformation allows
caspase-3 residues to interact with the β-strand inhibitor tightly in the active site groove. The P2
and P3 amino acid side chains of the inhibitor share very similar positions for their equivalent
atoms. The differences in the size and type of amino acid at P2 and P3, as well as the presence of
P5 in one inhibitor, however, are expected to lead to the potency differences of the three
inhibitors.
Caspase-3 showed very similar interactions with the main chain atoms of P1-P4 and the
Asp side chains at P1 and P4 of the analogs in all three structures (Fig 3.4 and Tab 3.2). In the
structure of caspase-3/DEVD, the side chain of Asp at P1 has ionic interactions with Arg 64 and
Arg 207 and a hydrogen bond interaction with Gln 161 in the S1 pocket (Fig 3.4a). The main
chain amide of P1 Asp interacts with the main chain carbonyl oxygen of Ser 205. At the P2
position, the hydrophobic side chain of Val has van der Waals interactions with caspase residues
Tyr 204, Trp 206 and Phe 256. The negatively charged Glu at P3 interacts closely with Arg 207
forming an ionic interaction between their side chains and two hydrogen bond interactions
between their main chain carbonyl oxygen and amide groups. In addition, P3 Glu shows a watermediated interaction with Thr 62. The carboxylate side chain oxygens of P4 Asp form hydrogen
bond interactions with the side chain of Asn 208 and main chain amide of Phe 250. A water-
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mediated interaction is formed between main chain amide of P4 Asp and the main chain
carbonyl oxygen of Phe 250. At the N-terminus of the inhibitor, the acetyl protecting group
interacts with the main chain amide of Ser 209.
At P2 and P3, the protein-inhibitor interactions of caspase-3/DMQD (Fig 3.4b) differ
from those in the complex of caspase-3/DEVD. The polar side chain of P2 Gln is directed out of
the hydrophobic S2 pocket. At the P3 position, the long hydrophobic side chain of methionine
lies in the S3 pocket, but forms no specific interactions. Fortunately, the hydrogen bonds
between the main chain atoms of P3 and Arg 207 are conserved. Similar interactions are present
in both two inhibitor binding sites of this (p17/p12)2 structure.
The longer peptide analog Ac-VDVAD-Cho binds to caspase-3 in a similar manner to the
other two inhibitors at positions P1-P4 (Fig 3.4c). At the P2 position, the side chain of Ala forms
van der Waals interactions with hydrophobic residues in the S2 pocket. However, the
hydrophobic side chain of P3 Val has no contacts with nearby caspase-3 atoms, which is similar
to P3 Met in Ac-DMQD-Cho. At the P4 position, in addition to the hydrogen bond interactions
observed in the caspase-3/DEVD structure, another hydrogen bond is formed between the main
chain carbonyl oxygen of P4 Asp and main chain amide of Phe 250 (Tab 3.2).
The peptide analog Ac-VDVAD-Cho contains P5 Val, unlike the other two analogs. The
P5 main chain amide is positioned to interact with the side chain hydroxyl group of Ser 209, and
its carbonyl oxygen interacts with both the side chain hydroxyl group and main chain amide of
Ser 209 (Fig 3.4c). These three hydrogen bonds stabilize the main chain of P5 Val and help to
position its hydrophobic side chain in a hydrophobic cleft formed by the side chains of Phe 252
and Phe 250. The acetyl group, on the other hand, has moved out of the active site groove of
caspase-3 into the solvent. Therefore, caspase-3 forms specificity pockets for recognition of
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substrate residues from P5 to P1. The hydrophobic S5 pocket in caspase-3 has not been described
previously.
3.3.3. Conformational Change when Caspase-3 Binds the P5-Containing Peptide
The caspase-3 residues forming S5 in the structure of caspase-3/VDVAD undergo a
conformational change relative to the complexes with tetrapeptides (Fig 3.5). The S5 pocket is
formed by residues from loop4, which has moved towards loop1 by up to 2.9 Å for Cα atoms
compared to the positions in the complexes with tetrapeptides. This conformational change
partly closes the entire active site groove of caspase-3 and enables P5 Val to form good van der
Waals contacts with Phe 250 and 252. This more closed conformation of the substrate-binding
groove has not been reported for other caspase-3 structures. In contrast to previous suggestions
that the active site groove of caspase-3 is rigid (Ni, Li et al. 2003), our results indicate that the
loop4 region of caspase-3 near S5 is flexible, and it forms a mouth-like binding groove together
with loops 1, 2 and 3. This “mouth” can open to different extents to accommodate a variety of
substrates by an induced fit mechanism. These structures suggest that the loop1 and loop4
regions are flexible in physiological conditions and this flexibility contributes to the binding of
substrate. Other caspases may also have flexible binding sites formed by their four loops. This
observation provides valuable insight into the dynamic mechanism of caspase recognition and
binding of substrates.
3.3.4. Enzyme Kinetics and Relative Inhibition
Three substrate analogs Ac-DEVD-Cho, Ac-DMQD-Cho and Ac-VDVAD-Cho that
differ in the P2, P3, and presence of the P5 position, were assayed for inhibition of the caspase-3
activity (Tab 3.3). Overall, the three analogs showed similar potency as reversible tight-binding
inhibitors. Ac-DEVD-Cho, with the canonical sequence, was the strongest inhibitor with a Ki
value of 0.2 nM. Ac-VDVAD-Cho was five-fold weaker, and Ac-DMQD-Cho was the weakest
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with a Ki value of 1.9 nM. The Ki values were comparable to those reported in previous studies
(Mittl, Di Marco et al. 1997; Talanian, Quinlan et al. 1997).
Three colorimetric peptides Ac-DVAD-pNA, Ac-VDVAD-pNA and Ac-LDVAD-pNA
were designed based on the crystal structures to evaluate the importance of the P5 position for
specificity of caspase-3. These peptides were shown to be substrates of caspase-3 and the kinetic
parameters are listed in Table 4. The major differences were observed in the Km values, while the
kcat values showed little variation, which suggested that the P5 residue affected the binding
affinity. Caspase-3 showed the highest catalytic efficiency (kcat/Km) and lowest Km for AcLDVAD-pNA, about 40% higher than the values for Ac-DVAD-pNA. Similarly, the kcat/Km for
Ac-VDVAD-pNA was 20% higher than for Ac-DVAD-pNA. These results demonstrated that the
hydrophobic P5 residue has an important contribution to the recognition and hydrolysis of
substrates by caspase-3.
3.3.5. Roles of S2 and S3 in Substrate Recognition and Caspase-3 Activity
The three crystal structures of caspase-3 with peptide analogs that vary in the amino acids
at P2, P3 and the presence of P5 have demonstrated the molecular basis for substrate recognition.
Caspase-3 interactions with the three analogs are conserved for the P1 and P4 positions and
differ for P2, P3 and P5. Kinetic studies have indicated that the caspase-3 substrate preferences
at P1 and P4 are almost absolute, since only aspartic acid is acceptable at these two positions and
any substitution resulted in a dramatic decrease in the binding affinity (Talanian, Quinlan et al.
1997; Thornberry, Rano et al. 1997). In agreement with these studies, all the protein-inhibitor
interactions in S1 and S4 are strong and conserved in all three crystal structures (Tab 3.2). Unlike
P1 and P4, the substrate selectivity of caspase-3 can vary for P2 and P3 positions. Theoretically,
hydrophobic amino acids are preferred at P2, and hydrophilic amino acids are preferred at P3.
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This is confirmed by the 10-fold difference in Ki values for Ac-DEVD-Cho and Ac-DMQD-Cho
(Tab 3.3).
The S2 pocket has an important role in both substrate recognition and regulation of
caspase-3 activity. Previous studies suggested that various hydrophobic amino acid residues at
P2 bound with high affinity, while polar amino acids were weakly bound (Talanian, Quinlan et al.
1997; Thornberry, Rano et al. 1997). At the P2 position, the main chain atoms cannot form
hydrogen bonds with caspase-3. The affinity for P2 binding is therefore largely dependent on the
side chain atoms. Hydrophilic residues will be unfavorable in the hydrophobic S2 pocket.
Previous studies showed that a pyrrolidine ring bound in S2 can increase the inhibitory potency
of 1-Methyl-5-nitroisatin by 30-fold (Lee, Long et al. 2000). In our kinetic assay, Ac-DMQDCho showed twofold weaker inhibition of caspase-3 than did Ac-VDVAD-Cho (Table 3.3).
Similarly, the catalytic efficiency for hydrolysis of Ac-DMQD-pNA was 54% of the value for
Ac-DVAD-pNA and 17% of the value for Ac-DEVD-pNA (Tab 3.4). The structural explanation
is that the binding of polar P2 Gln in hydrophobic S2 is unfavorable and decreases the binding
affinity of the inhibitor, although the P5 position will also have an effect. Nevertheless, the CB
and CG atoms in the long side chain of P2 Gln form favorable van der Waals interactions with
residues in the S2 pocket. Therefore, the inhibition is not greatly decreased. The S2 pocket
appears to have a role in regulation of caspase-3 activity. The crystal structure of caspase-3 in
complex with the inhibitor of apoptosis protein XIAP showed that the side chain of Tyr 204 was
rotated into the S2 pocket and blocked the binding of substrate (Riedl, Renatus et al. 2001). Also,
the side chain of Tyr 204 filled the S2 pocket in the structure of an unliganded caspase-3 (Ni, Li
et al. 2003). These results suggest that the S2 pocket has an important role in both substrate
recognition and regulation of caspase activity.
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The P3 position can tolerate a wide range of amino acids. Although negatively charged or
polar amino acids have better binding affinity, some non-polar amino acids such as valine and
alanine can also bind in the S3 pocket quite stably (Talanian, Quinlan et al. 1997; Thornberry,
Rano et al. 1997). Analysis of our structures showed that the hydrogen bond interactions formed
between the main chain atoms of P3 residue and Arg 207 are conserved in all three structures
(Tab 3.2). These interactions stabilize the P3 residue in the correct location, independent of the
type of side chain. Hence, the P3 residue can vary without significantly altering the binding
affinity.
3.3.6. Role of S5 Pocket in Caspase Recognition of Substrates
The structure of caspase-3/VDVAD shows that the side chain of P5 Val lies in a
hydrophobic cleft formed by two aromatic residues in the loop4 region, Phe 250 and Phe 252
(Fig 3.6b). Moreover, the caspase-3 loops forming the binding site had a conformational change
relative to the two complexes with tetrapeptides, suggesting that the P5 residue of a pentapeptide
bound by an induced fit mechanism. The importance of a hydrophobic P5 residue for binding
and hydrolysis of caspase-3 substrates was confirmed by our kinetic assays showing kcat/Km
values in the order Ac-LDVAD-pNA > Ac-VDVAD-pNA > Ac-DVAD-pNA (Tab 3.4). Because
the P5 residue is located at one end of the major active site groove of caspase-3, polar sidechains are free to rotate into the solvent and away from the hydrophobic S5 site, which might
explain why little apparent substrate preference at P5 has been observed previously for caspase-3.
Nevertheless, hydrophobic residues at P5 enhance the binding affinities and specificities of the
tested caspase-3 substrates. In contrast, the addition of the hydrophobic P5 residues had the
opposite effect on hydrolysis by caspase-7, and the kcat/Km values were in the reverse order of
Ac-DVAD-pNA>Ac-VDVAD-pNA>Ac-LDVAD-pNA (Tab 3.4). This discovery of the S5
recognition site in caspase-3 will be helpful for the future design of novel inhibitors.
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Previous work on caspase-2 has revealed that the addition of a hydrophobic P5 residue
can increase the Vmax/Km value of its substrate (Talanian, Quinlan et al. 1997), underscoring the
critical role of the S5 pocket, and consistent with the observed interactions in the caspase2/LDESD crystal structure (Schweizer, Briand et al. 2003). The main chain conformations of the
two bound pentapeptides are very similar in the structures of caspase-2/LDESD and caspase3/VDVAD (Fig 3.6a). Also, the hydrogen bond and van der Waals interactions of P5 in the S5
binding pocket are similar in caspase-3 and caspase-2 (Fig 3.6b and c). The main chain amide
and carbonyl oxygen of the P5 residue form hydrogen bond interactions with Ser209 of caspase3 or with Thr233 of caspase-2. The hydrophobic P5 side chain has van der Waals contacts with
structurally equivalent hydrophobic side chains from loop4 in both caspase-2 and -3. In caspase2, the P5 Leu interacts with Tyr273 and Pro275, while in caspase-3 P5 Val interacts with Phe250
and Phe252.
No apparent substrate selectivity at P5 has been reported for other caspases. Therefore,
the potential S5 binding site formed by residues of loop4 was examined for other caspases of
known structure. The sequences and structures of six human caspases (caspase-1(Wilson, Black
et al. 1994), 2(Schweizer, Briand et al. 2003), 3, 7(Chai, Wu et al. 2001), 8(Watt, Koeplinger et
al. 1999), and 9(Chao, Shiozaki et al. 2005)) are compared in Figure 3.7 and 3.8. These six
caspases have diverse sequences and lengths for the loop4 regions (Fig 3.7), suggesting that they
will vary in their substrate specificity. The loop4 regions of caspase-2, -3 and -7 have similar
lengths and conformations. Caspase-2 and -3 have two aromatic residues forming the S5 pocket;
while the polar Gln and Asp were located at the equivalent positions of caspase-7. We therefore
predict that either caspase-7 forms a hydrophilic S5 pocket, or else it has no preference for the
type of residue at the P5 position. These differences in substrates recognition of caspase-3 and –7
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are likely to result in different cellular effects, including activation of distinct signaling pathways.
The other three caspases, -1, -8 and -9, have shorter loop4 regions and may not be able to form
an S5 binding pocket (Fig 3.8). Therefore, these caspase proteins are likely to differ in their
recognition of the P5 position of their substrates.
3.4. Conclusions
Our crystal structures of caspase-3 with three different peptide inhibitors have revealed
the molecular basis for substrate preferences at P2, P3, and suggested the preference for
hydrophobic side chains at P5. The importance of the hydrophobic P5 residue was confirmed by
studies of caspase-3 activity on substrates with different P5 residues. The newly defined
hydrophobic S5 pocket of caspase-3 is similar to the S5 pocket in caspase-2, but polar residues
are found in equivalent positions of caspase-7, suggesting that these caspases will differ in their
substrate selectivity at P5. Moreover, caspase-1, 8 and 9 are unlikely to have similar S5 binding
pockets on the basis of their structures. These discoveries will be valuable for the future design
of novel inhibitors that are more specific for caspase-3. The distinct preferences observed for the
P5 residue in caspase substrates will help define the particular cellular signaling pathways
associated with each caspase protein.
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Table 3.1. Crystallographic Data Collection and Refinement Statistics
Structure
Inhibitor

Caspase3/DEVD
Ac-DEVD-Cho

Caspase3/DMQD

Caspase3/VDVAD

Ac-DMQDCho
P21

Ac-VDVADCho
P21

Space group

I222

A (Å)

69.9

50.2

50.4

B (Å)

86.1

69.3

69.7

C (Å)

98.0

94.1

93.4

β

90°

102°

101°

Resolution (Å)

50-1.7

50-2.0

50-2.3

Data range for refinement
(Å)
Completeness overall (last
shell) (%)

10-1.7

10-2.0

10-2.3

85.9 (79.0)

94.7 (66.9)

97.6 (89.4)

R merge overall (last shell)
(%)

12.5 (36.4)

7.1 (24.5)

8.8 (40.2)

I/sigma overall (last shell)

14.0 (3.3)

9.7 (3.0)

12.0 (2.0)

Rwork (%)

19.5

20.3

22.7

Rfree (%)

23.7

27.2

25.4

Number of waters

240

593

86

Bonds

0.011

0.015

0.007

Angle

0.03a

0.025a

1.3b

Main chain

14.5

21.2

27.9

Side chain

23.5

27.8

32.3

Inhibitor

18.4

24.1

36.4

RMS deviation (Å)

Average B-factor (Å)

a. In SHELX97, the angle RMS deviation is indicated by distance in Å; b. Structure
refined with CNS where the angle RMS deviation is indicated by angle in degrees.
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Table 3.2. Polar interactions of caspase-3 with peptide analogs
Distance (Å)
Analog
atoms

P1 Asp N

Protein atoms

Ac-DEVD-Cho

Ac-DMQD-Cho

Ac-VDVAD-Cho

Chain E/F

Chain E/F

Ser205 O

3.0

2.9/2.9

2.8/2.8

Asp OD1

Arg64 NE

2.9

2.7/2.8

2.6/2.7

Asp OD1

Arg207 NE

2.9

2.8/2.8

3.2/3.4

Asp OD1

Arg207 NH1

3.1

3.0/2.8

2.8/3.1

Asp OD2

Arg64 NH1

2.9

2.9/2.9

2.9/2.6

Asp OD2

Gln161 NH2

2.9

2.9/2.9

3.2/3.1

P3 E/M/V N

Arg207 O

2.8

2.6/2.8

2.8/2.8

E/M/V O

Arg207 N

2.9

2.8/2.8

2.8/3.0

E OE1

Arg207 NH2

2.9

Asn208 ND2

3.1

2.9/2.9

2.8/2.9

Asp OD2

Phe250 N

3.1

3.0/3.0

3.1/3.2

Asp N

Phe250 O

3.0/3.2

P5 Val O

Ser209 N

3.0/2.8

Val O

Ser209 OG

2.9/2.6

Val N

Ser209 OG

3.0/2.8

Ace O

Ser209 N

P2

P4 Asp OD1

2.9

2.7/2.9
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Table 3.3: Inhibition constants
Inhibitor

Ki (nM)

Ac-DEVD-Cho

1.3 ± 0.1

Ac-VDVAD-Cho

6.5 ± 0.4

Ac-DMQD-Cho

12.4 ± 0.7

Caspase-3 activity was assayed using the substrate Ac-DEVD-pNA and
the Km value was 67±4 μM. Ac indicates the acetyl group and Cho
represents the aldehyde group. Caspase-3 was preincubated with its
inhibitors in reaction buffer (50 mM HEPES, 100 mM NaCl, 0.1%
CHAPS, 10% glycerol, 1mM EDTA and 10 mM dithiothreitol, pH 7.5)
at room temperature for 15 mins. Substrate was then added and reaction
product p-nitroanilide was measured at a wavelength of 405 nm. The
inhibition constants were determined by using the equation: Ki = (IC500.5[E])/(1+[S]/Km), where [E], [S] and IC50, respectively, correspond to
active enzyme concentration, substrate concentration, and the inhibitor
concentration needed to suppress half enzyme activity. The enzyme
concentration was determined by active site titration.
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Table 3.4: Kinetic parameters of caspase-3 substrates
kcat (min‐1)

kcat/Km (mM‐1min‐1)

Km (μM)

C3

C7

C3

C7

C3

C7

DEVD

53.1±3.2

NA

67.1±4.3

NA

790.4±47.4

NA

DMQD

211.8±12.7

NA

1600.3±96.0

NA

132.4±7.9

NA

DVAD

54.2±1.8

56.8±1.1

222.3±7.3

219.3±4.4

243.8±8.0

259.0±5.2

VDVAD

48.4±1.6

75.6±2.3

164.7±5.4

314.9±9.4

293.9±9.7

240.1±7.2

LDVAD

50.6±1.5

66.1±1.3

147.2±4.4

323.9±6.5

343.8±10.3

204.1±4.1

Caspase-3 was preincubated in reaction buffer (50 mM HEPES, 100 mM NaCl, 0.1% CHAPS,
10% glycerol, 1mM EDTA and 10 mM dithiothreitol, pH 7.5) at room temperature for 5 mins
prior to the addition of substrates at various concentrations. p-nitroanilide released by enzyme
cleavage was measured at a wavelength of 405 nm using a Polarstar Optima microplate reader.
Km and Vmax values were determined by fitting the Michaelis-Menten plot:
V=Vmax[S]/(Km+[S]) where [S] refers to substrate concentration. The catalytic constants kcat
of caspase-3 substrates were determined by the equation kcat=Vmax/[E], where active enzyme
concentration [E] was measured by active site titration.
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L4

DMQD

C17

L3
L1
L2

E

A

B

D

C

C12
N17

N12

F

Figure 3.1. Overall structure of caspase-3/DMQD. Two heterodimers (p17/p12)2 of caspase3/DMQD are shown in a ribbon representation with the large and small subunits colored blue
and grey, respectively. The inhibitor Ac-DMQD-Cho is shown in a yellow ball and stick
representation. The four polypeptide chains are labeled A to D and the two peptide analog
inhibitors are labeled E and F. The N and C-termini are indicated for the 12 and 17 kD chains.
L1 to L4 refer to Loops 1 to 4.
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DMQD
L4

A

L1

L3
B

H121

C163
L2

Figure 3.2. His121 has different side-chain conformations in the two p17/p12 heterodimers
of caspase-3/DMQD. The A conformation of the His 121 side-chain lies in the active site groove,
while conformation B is closer to the catalytic Cys163. The active site groove is formed by
residues from the four loops (L1–L4). The peptide analog Ac-DMQD-Cho is shown in cyan.
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P5
P4
P3
P2
P1

(a)

(b)

Figure 3.3. Structure of peptide analog inhibitors. (a) 2Fo – Fc electron density map of AcDEVD-Cho in the caspase-3/DEVD complex. The map was contoured at a level of 1.8σ. The
active site Cys163 of caspase-3, located at the bottom, forms a hemithioacetal bond with the
aldehyde group of the inhibitor. Inhibitor P1–P4 residues and the acetyl group are labeled. (b)
Superposition of the three peptide analogs Ac-DEVD-Cho (green), Ac-DMQD-Cho (orange),
and Ac-VDVAD-Cho (purple). The equivalent atoms on both the main chain and side chain have
similar positions from P1 to P4.
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(a)

(b)

(c)
Figure 3.4. Schematic representation of the caspase-3 interactions with inhibitors. (a)
caspase-3/DEVD, (b) caspase-3/DMQD, and (c) caspase-3/VDVAD. The substrate analog
inhibitors are indicated by thicker lines. Inhibitors are covalently linked to the active site Cys163
via a thioether bond. Hydrogen bonds and salt bridges are indicated by dashed lines. Van der
Waals interactions are shown as thick curves.
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21.0Å
18.1Å

21.0Å
18.1Å

Caspase-3/VDVAD

Caspase-3/DEVD

(a)
Phe252

3.8Å 6.2Å
6.3Å
4.4Å

Phe250
P5 VAL

(b)
Figure 3.5 The superimposed complexes of caspase-3/DEVD and caspase-3/VDVAD. (a)
Stereoview of Cα backbone of caspase-3/DEVD (yellow) and caspase-3/VDVAD (green). The
complex with P5 residue has a narrower active site groove, as reflected by the indicated distances.
The boxed region is shown in detail in (b) where the S5 residues of Phe 250 and 252 on the
loop4 form van der Waals contacts with the P5 Val of the substrate analog. Distances between
atoms are shown by dashed lines.
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P5
L3
P3

P4

L4

P1

L1

P2

L2

(a)
Phe252

3.8

Pro275

4.0
3.5

4.6

P5 Leu

P5 VAL

4.3

3.7

4.4
3.0
3.0

2.9
3.0

Phe250

Ser209

(b)

Tyr273

2.9

Thr233

(c)

Figure 3.6. Structural comparison of caspase-3 and caspase-2. (a) Comparison of interactions
of substrate analogs VDVAD (red) and LDESD (green) with caspase-3 and -2. The substrate
binding groove is formed by four loops labeled L1 to L4. The inhibitor amino acids from P1 to
P5 are labeled. Protein-inhibitor interactions are compared in the S5 pocket of (b) caspase-3 and
(c) caspase-2. The P5 residue of the inhibitor was located in the middle. Its interactions are
indicated by dashed lines. Hydrogen bond interactions and hydrophobic interactions are
indicated by black and green dashed lines respectively. Distances between atoms are shown in
angstroms.
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Loop4
Figure 3.7. Sequence homology among six caspase family members. Only the regions of the small subunits including loop3 and
loop4 are compared. The loop4 regions from sequence alignment are shown in the red box. The loop4 regions defined from the crystal
structures, are indicated by the green letters. The S5 residues of caspase-2 and -3, as well as the residues at equivalent positions of
caspase-7, are colored red.
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Pro 4

1

Tyr

1

2

3

2
3

2

2

Caspase-7
4

1
3

Gln

3

Caspase-3

4

Asp 4

1

2

3

Caspase-2

1

Phe 4
Phe

1

4
3
2

Caspase-1

Caspase-8

Caspase-9

Figure 3.8 Different compositions of active site groove. The structures of the active site grooves of six human caspase family
members are shown. The numbers 1 to 4 indicate the loops 1-4. Hydrophobic protein residues are colored blue, and hydrophilic ones
are colored red. The loop4 regions are longer in caspase-2, 3 and 7. The S5 residues on the loop4 of caspase-2, 3 as well as the
equivalent residues of caspase-7 are labeled.
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4. COMPACT, DIFFERENTIABLE, KNOWLEDGE-BASED POTENTIAL
FUNCTIONS FOR EVALUATING PROTEIN MODEL QUALITY
4.1. Introduction
An effective and efficient potential function is required for protein structure prediction.
There are currently two major categories of potential functions: physical-based potentials and
knowledge-based potentials. The physics-based potentials are the summation of non-bonded
electrostatic and van der Waals interaction energies. Numerous factors have to be considered for
this method, such as bond length, angle, dihedral angle, entropy, and solvent effects (Brooks and
Bruccol 1983; Jorgensen, Maxwell et al. 1996; Lazaridis and Karplus 1999). However, this
physics-based potential is becoming less and less popular for protein structural prediction due to
expensive computation. In contrast, the knowledge-based potentials provide a more efficient way
of assessing potentials and thus have become widely used (Zhou, Zhou et al. 2006). The typical
knowledge-based potential is built on the mean potentials from the distribution of pairwise
distances of experimentally determined protein structures (Zhou, Zhou et al. 2006). Boltzman’s
law is used to calculate the interaction energy between a particular particle pair (Sippl 1990).
And the entire potential is considered as the summation of all pairwise potentials. Usually one
residue is represented by one interacting point, such as Cα, Cβ, and side chain center of mass
(SCM) (Zhang, Liu et al. 2004; Fogolari, Pieri et al. 2007). This type of potential is called
residue-level potential. All atoms or residue specific heavy atoms were also used for representing
residues in many successful models (Zhou and Zhou 2002; Makino and Itoh 2008; Mirzaie,
Eslahchi et al. 2009). Their potentials are called atomic-level potentials.
Although current knowledge-based potential functions achieved good performance in
protein structure prediction (Zhou, Zhou et al. 2006), molecular mechanics is still dominated by
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physical-based potentials. This is because of the common limitation of current knowledge-based
potentials. The potential curve of the knowledge-based function is built from a series of discrete
points defined by distance-potential pairs. Each point represents the values of a certain distance
bin and is independently determined by the statistical analysis of the entire protein structure. It
means the relation between potential energy and pairwise distance is not directly described by a
mathematical function. This makes the calculation of molecular mechanics difficult because the
force exerted on a particle is determined by the gradient of the potential function (Alder and
Wainwright 1959) and the gradients cannot easily be obtained for potential functions consisting
of discrete points.
In order to overcome the limitations of current knowledge-based potentials, here we
designed a novel method of constructing knowledge-based potentials. The potential energies of a
pair of residues of a certain type of amino acid, such as nonpolar-nonpolar pair, or chargedcharged pair, should follow a certain pattern although there must be some variation between
different pairs of residues. Therefore, a small number of potential patterns can be used to
represent the potential energies of all the residue pairs. Based on this assumption, if we can find
a polynomial expression to describe each potential pattern, the potentials of all the residue pairs
can be defined by a set of polynomial expressions. Then the total potential can be easily
calculated. The atomic-level potentials can also be obtained using the same strategy, but it will
be more complex since more potential patterns might be needed. The advantage of our proposed
method is that we do not need to consider how the potential is derived from either physical laws
or statistical analysis, the only thing we need is a number of mathematical expressions
determined by regression, which can reflect the natural properties of protein potentials.
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Since polynomial expressions need more computational power to be determined, we
started from using simple, physical equations to approximate potential energies. Physical

potential functions like Gaussian:

potentials:

(

⎡⎛ b ⎞12 ⎛ b ⎞6 ⎤
E = 4a ⎢⎜ ⎟ − ⎜ ⎟ ⎥
⎢⎣⎝ r ⎠ ⎝ r ⎠ ⎥⎦

E = D 1− e

− a ( r − rk )

E = ae

−

( r − b )2
2c2

(Lennard-Jones

(Laplace 1812), Lennard Jones 6/12

1924),

and

Morse

potentials:

) (Morse 1929) have the desirable feature of converging to a constant at
2

large distances, which is not true, in general, with polynomial expansions. Therefore they are
well suited to use in expansions of inter-residue and inter-atomic potentials. In this study, the
Morse potential function showed the best outcome among a number of models we have tested.
Although different types of residue pairs have distinct potential patterns, we simplify this
problem by using the Morse potential curve to approximate the potentials of all residue pairs.
Thus the potential values in this study are considered as “pseudo” or “relative” potentials.
Unless specified, protein residues are represented by the side chain center (SCM) of mass in this
study. Since our potentials are defined by many fewer parameters than other knowledge-based
potentials, we name the entire set of 210 potential functions as the Compact-SCM.
4.2. Materials and Methods
4.2.1. Calculation of Total Potential
In our study, the total potential of mean force for a protein was approximated as the sum
of pairwise potentials of all the residues. The potential of each different residue pair was defined
by one potential function. Therefore, 210 functions were determined for the total potential of a
protein. The Morse potential function was used to approximate the potential of mean force u(i, j,
r) between two residues i and j at the distance r:
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u (i, j ,r )= De (1−e− a ( r −re ) )2
re refers to the equilibrium distance between two residues, a and De control the width and depth
of the potential curve respectively. The ranges of three parameters were set to: 1≤De≤6,
0.3≤a≤3.0, and 0<re<14. The basic step sizes were 1, 0.1, and 0.1 for tuning De, a and re,
respectively. For each residue pair ij, one triple (De, a, and re) was determined for its unique
potential function. Thus, a total number of 630 parameters (210 triples) were determined for 210
potential functions. Finally, the total potential of mean force u for a given protein was calculated
as:

u (i , j , ∞ ) =

1
∑ u (i , j ,rij ) − ∞
2 i, j

Since the potential energy of a well formed protein molecule is negative, the value at infinity (∞)
was subtracted to ensure negative values of the potential energy. In this study, the position of
each residue was represented using three different approaches: Cα atom, Cβ atom, and side chain
center of mass (SCM).
4.2.2. Parameter Determination Using Genetic Algorithm
Genetic algorithm is particularly effective for tuning large number of variables (Kaufman
1998). In this study, a vector containing 630 parameters with designed initial values was
considered as an individual chromosome. Each population was formed by 30 distinct
chromosomes. The elitism selection (Mashohor, Evans et al. 2005) was applied in reproduction.
Combination rate and mutation rate were 90% and 1%, respectively. The selection pressure was
the rank of the native fold in the decoy sets. The parameters were tuned for over 300 parallel
cycles on the Octans cluster at Georgia State University. In each cycle, 4 to 6 decoy sets were
used simultaneously. A set of 630 parameters were generated only if the potentials of all the
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native structures in tested decoy sets were correctly ranked to the 1st. The final parameter set
was produced in the integration step, where all sets of produced parameters were analyzed and
the most frequent value for each parameter was extracted as the final value. The averaged values
were also tested in our study, but the result was worse than the most frequently appeared values.
4.2.3. Training Data and Decoy Sets
The training data contains decoys from CASP6 and 4state_reduced (Park and Levitt
1996). CASP6 decoys were downloaded from http://predictioncenter.org/casp6. Among those
decoy sets, only X-ray structures of monomer proteins without gaps were selected. Specifically,
18 decoy sets (t0199, t0200, t0201, t0262, t0263, t0264, t0267, t0268, t0269, t0271, t0273, t0274,
t0275, t0277, t0279, t0280, t0281), each containing 60 decoy structures on average, were
selected as part of our training data. Because most proteins in CASP6 are relatively big (100-300
residues), seven 4state_reduced decoy sets from http://dd.compbio.washington.edu/download.
shtml (1ctf, 1r69, 1sn3, 2cro, 3icb, 4pti, 4rxn), were added to our training data set to minimize
the bias towards the protein size. Each native structure in this decoy sets has 50-70 residues and
each decoy set contains about 660 decoy structures on average. Training decoys were preselected
by removing structures with gaps, missing atoms, incomplete or longer sequences. The testing
decoy sets are listed in the Table 1. All the decoy sets were used for the tests of Cα and Cβ
representations while two groups of decoys were used on the examination of SCM representation.
One group contains all the 70 multiple decoys and the other group only contains the filtered
decoys. Decoys marked with * in the Table 1 were discarded during the filtering as missing side
chain atom was found in the PDB file of the native structure. The docking decoy sets were
downloaded from http://www.sbg.bio.ic.ac.uk/docking/all _decoys.html.
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4.2.4. Performance Measurement
Z-score is the difference from the mean divided by the standard deviation. It places
values of the potential in a “standard measure” and reflects the degree to which a value at an
individual is distinct from the values at the rest of the data points. It reflects the bias towards the
native structure (calculation follows the standard definition (Zhang, Liu et al. 2004)). CC refers
to correlation coefficient between Cα rmsd and calculated potential energy. FE represents
fraction enrichment which means the percentage of the top 10% best scoring structures that are
also found in the top 10% lowest rmsd structures.
4.3. Results and Discussion
4.3.1. Parameters Determined for 210 Potential Functions
Ideally, different residue pairs will have distinct potential trajectories, especially for
different types of residue pairs, such as nonpolar-nonpolar pairs and charged-charged pairs. We
simplified this complication by approximating the potentials of all residue pairs by one type of
trajectory. However, we set a wide value range for each adjustable variable in the potential
function, allowing the potential curves to be different from one to another. We tested four types
of potential curves defined by single Gaussian’s function (Laplace 1812), double Gaussian
function, Lenard-Jones function (Lennard-Jones 1924), and Morse function (Morse 1929),
respectively. As shown in Figure 4.1, the Morse potential curve showed the best accuracy in our
test. The genetic algorithm successfully generated 630 parameters for 210 potential functions.
Although there are 210 functions, only a narrow range of values were selected for each variable
after training. All 210 functions have the same De value of 5.0. The majority functions have their
a values in the range of 0.5±0.2 (Table 4.2) although several exceptions exist. In contrast, a
variety of values from 4.3 to 8.1 were selected for the parameter re as indicated in the Table 4.3.
Since the re defines the equilibrium distance between two residues, it suggests that our method
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tends to use the equilibrium distance as the most important feature to distinguish potentials of
different residue pairs. The opening width of the potential curve, which is determined by a, also
plays some roles for the discrimination. The well depth of the potential curve, however did not
contribute to the discrimination. By analyzing single potential function, correlation between the
shape of the curve and the residue type was not observed. This is not surprising as our
approximated potentials were designed to function as an intact system.
4.3.2. Performance on 70 Standard Multiple Decoy Sets
In previous studies, it was suggested that a residue can be represented by a single
interaction point instead of all the atoms. The potential function using side chain center of mass
(SCM) showed the most comparable result to the atomic level potentials (Zhang, Liu et al. 2004).
In order to find out the most efficient residue representation for our model, three most widely
used approaches, Cα, Cβ, and SCM, were tested. The success rates on 70 decoy sets increased
significantly from 30%, 46% to 70% as the interaction center moved from Cα, Cβ, to SCM. We
subsequently compared the performance of the Compact-SCM with three previously published
models using the SCM representation. The performance data of KBP, RAPDF, and DFIRE-SCM
was obtained from the previous study of Zhang (Zhang, Liu et al. 2004). The detailed
comparison was shown in the Table 4.4.
The lattice_ssfit decoy set was generated by tetrahedral lattice model with all-atom
ENCAD energy function (Xia, Huang et al. 2000). The original package has 2000 decoys for
each of eight targets. The performances of the Compact-SCM were quite different on filtered and
non-filtered decoys. 5 targets were correctly ranked out of 8 non-filtered decoy sets while all
three filtered decoy sets were correctly ranked. Our average Z-scores were lower than other three
methods. The lmds was generated by a local minimization method with a reduced ENCAD
function (Keasar and Levitt 2003). The best success rate of three previous methods on this decoy
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was 3/10. Our method achieved comparable performance for both filtered and non-filtered
decoys. The fisa and fisa_casp3 decoy sets were generated by simulated annealing method with
Bayesian scoring function (Simons, Kooperberg et al. 1997; Simons, Bonneau et al. 1999). Our
method successfully rated all the seven targets while all other three approaches missed at least
one target. Our average Z-score for fisa decoys was comparable to other methods whereas it is
somehow lower for the fisa_casp3 decoys. Among 10 filtered targets of CASP4 decoys, our
method discriminated 7 native structures. The accuracy is a little better for the non-filtered
decoys. The success rate and average Z-score were both lower than other three methods. In
contrast, our method achieved 79% of success for 24 Rosetta targets and only DFIRE-SCM got
the similar accuracy. All together, the Compact-SCM achieved an average accuracy of 70% for
the entire 70 non-filtered decoy sets, which is close to the DFIRE and better than other two
methods. However, if only the filtered decoys are considered, the Compact-SCM achieved an
accuracy of 73% which is better than all other three methods. Considering that the performance
of knowledge-based potential relies on the training data, it is necessary to exclude low quality
structures from the training set. Similarly, the non-filtered testing set can possibly generate false
result due to the ignoring of missing side chain atoms or even residues. Therefore, our result for
the filtered decoy sets is more reliable than other three methods. In addition, we discarded model
structures having gaps or sequence differences from the native structure by filtering, thus some
decoys far from the native conformation were excluded from our testing data. This could result
in the decrease on the average Z-score for the filtered decoys.
Many knowledge-based potential functions were developed in recent years, some of
which use different residue representations other than the SCM. We therefore compared the
performance of Compact-SCM with some other methods. The data of comparison was obtained
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from (Makino and Itoh 2008) for DFMAC and (Mirzaie, Eslahchi et al. 2009) for all other
methods. To exclude the possible training bias of different studies, only commonly tested decoys
were compared. The number of correctly ranked targets for each decoy set is shown in the Table
4.5. Our method correctly rated 13 targets out of 19 decoy sets, which is significantly higher than
the Rosetta and three ModPipe methods. However, DFIRE-A, DOPE, PC2CA, and Force model
all got 15-17 correct rankings. This result, however, is not surprising because those methods use
more complicated residue representations. DFIRE-A, DOPE, and Force model use residue
specific heavy atom representation, and the PC2CA use both Cα and SCM information. The
DFMAC is a recently reported method using only main chain atoms. Although its success rate
was 6/8 in our comparison, its tested decoy set was significantly less and our method got the
same success rate if only the same decoy sets were counted.
CC and FE are other two parameters used in assessing the ability to discriminate the
native fold from structural models. In this study, the average CC and FE for all 70 multiple
decoy sets were 30% and 20%, respectively. The best average CC was 61% on Casp4 decoy set.
And our results on lattice_ssfit, fisa, fisa_casp3 and lmds decoy sets were similar to the DFMAC
(Makino and Itoh 2008). Clearly, the correlation between rmsd and potential score is not
significant for our method. Nevertheless, to achieve a significant correlation coefficient for a
large number of decoy sets is still a very challenging problem and most studies can only obtain
good results on some particular decoy sets (Makino and Itoh 2008) (Zhou and Zhou 2002).
Overall, the Compact-SCM has demonstrated one of the best performances among
methods using the SCM representation. Although the performance is moderate compared with
some atomic-level potentials, it is likely due to the limit of the SCM representation. Moreover,
our method uses significantly fewer adjustable parameters than those used in other methods
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(about 90% fewer than other residue level potentials (Table 4.4) and over 99% fewer than atomic
level potentials (Table 4.5)). It suggests that our potential function captures the hidden features
of potential energy better than other methods and thus is more statistically significant. Last but
not least, although improving the correlation between rmsd and function score is a challenging
task, future development will benefit since the construction method of our potentials is much
simpler and more flexible than other studies.
4.3.3. Performance on 9 Docking Decoy Sets
In the study of Zhang (Zhang, Liu et al. 2004), the performance of DFIRE-SCM was
tested by 21 docking decoys sets. To understand Compact-SCM’s capability of discriminating
docking decoys, we performed the same test using 9 decoy sets available at
http://www.sbg.bio.ic.ac.uk/docking/all_decoys.html. Four decoy sets contain dimer interfaces
and five contain trimer interfaces. The performance of Compact-SCM was compared with the
LLS (all atom version) (Lu, Lu et al. 2003) and the DFIRE-SCM (data from (Zhang, Liu et al.
2004)). The ranking of native structure for each decoy set is indicated in the Table 4.6. For the
dimer decoys, our method successfully rated 3 out of 4 native structures, which is equivalent to
the LLS and a bit lower than the DFIRE-SCM. For the trimer decoys, our method correctly rated
4 native structures out of 5. DFIRE-SCM got the same accuracy while LLS got only 1 hit.
Overall, the performance of Compact-SCM was much better than the LLS and comparable to the
DFIRE-SCM. This result indicated that the Compact-SCM has considerable capability of
discriminating docking decoys. Since the Compact-SCM was not trained with any interface
decoys, the performance has a good chance to be enhanced in the future.
4.3.4. Conclusions and Future Work
We introduced a new method of generating knowledge–based potentials that can be used
for both structural prediction and molecular mechanics. The potential of mean force for each
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residue pair was defined by one Morse function determined by training against 25 sets of
multiple decoys. The total potential of mean for a protein was calculated as the summation of all
residue pairs. The capability of the Compact-SCM on discriminating native structure from
structural models was comparable to some of the best models using residue-level potentials.
What’s more, each potential function was described by only three parameters (De, a, and re),
which is much less (<10%) than other potentials. And derivatives of each potential functions on
the distance can be easily calculated. These advantages make the Compact-SCM favorable for
both structure prediction and molecular mechanics.
The development of our potential functions is still in progress. We are testing more
mathematical models to approximate the potential patterns. The Morse function will be further
refined by integrating auxiliary expressions. Meanwhile, we are trying to distinguish different
types of residue pairs using different mathematical expressions. And we will eventually establish
a set of atomic-level potential functions. With the further development, we believe the
performance of our potential functions will be considerably enhanced. This new type of
knowledge-based potentials will help the future studies of structural bioinformatics.
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Table 4.1. 70 multiple decoy sets for testing.
Source

Average decoys

PDB ID

lattice_ssfita

1998

1beo, 1ctf, 1pgb, 1dtk-A*, 1fca*, 1nkl*, 1trl-A*, 4icb*

lmdsb

445

1b0n-B, 1bba, 1ctf, 1dtk, 1fc2, 1igd, 1shf-A, 2cro, 2ovo, 4pti*

fisac

500

1fc2, 1hdd-C, 2cro, 4icb

fisa_casp3d

1498

1bg8-A, 1bl0, 1jwe

CASP4e

37

t0092(1im8), t0098(1fc3), t0100(1qjv), t0103(1ga6), t0104(1fl9), t0108(1j83),
t0115(1fwk), t0117(1j90), t0123(1exs), t0125(1ghk), t0086(1fw9)*,
t0087(1i74)*, t0096(1e2x)*, t0106(1ijx)*, t0107(1i8u)*, t0111(1e9i)*,
t0112(1e3j)*, t0113(1e3w)*, t0118(1fzr)*, t0121(1g29)*, t0126(1f35)*

Rosettad

846

1aa2, 1acf, 1ail, 1bdo, 1csp, 1ctf, 1erv, 1gvp, 1kte, 1mbd, 1msi, 1pal, 1pdo,
1r69, 1ris, 1tul, 1utg, 1vls, 1who, 2acy, 2fha, 4fgf, 2gdm, 5icb

a

(Xia, Huang et al. 2000), b (Keasar and Levitt 2003), c (Simons, Kooperberg et al. 1997), d (Simons, Bonneau et
al. 1999), e (Feig and Brooks 2002)
*decoys not tested for SCM approach due to the missing side chain atoms in the native structure.
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Table 4.2. Values of the parameter a for each residue pairs.
A
C
D
E
F
G
H
I
K
L
A 0.5 0.4 0.7 0.6 0.3 0.5 0.7 0.4 0.6 0.6
C
0.5 0.3 0.6 0.5 0.5 0.7 0.5 0.7 0.5
D
0.6 0.5 0.5 0.6 0.5 0.5 0.3 0.5
E
0.7 0.6 0.6 0.4 0.7 0.7 0.6
F
0.3 0.6 0.5 0.4 0.4 0.3
G
0.6 0.4 0.7 0.5 0.5
H
0.5 0.6 0.4 0.5
I
0.5 0.7 0.6
K
0.7 0.7
L
0.6
M
N
P
Q
R
S
T
V
W
Y
.

M
0.5
0.3
0.5
0.5
0.3
0.6
0.7
0.3
0.3
0.5
0.5

N
0.6
0.4
0.5
0.4
0.7
0.5
0.5
0.6
0.6
0.5
0.5
0.5

P
0.7
0.5
0.7
0.7
0.5
0.7
0.6
0.7
0.5
0.7
0.7
0.6
0.7

Q
0.5
0.5
0.5
0.6
0.5
0.4
0.5
0.6
0.3
0.6
0.4
0.5
0.5
0.5

R
0.7
0.4
0.7
0.6
0.3
0.3
0.7
0.7
0.7
0.3
0.5
0.5
0.7
0.7
0.6

S
0.6
0.5
0.5
0.6
0.5
0.5
0.5
0.6
0.5
0.7
0.5
0.4
0.5
0.5
0.6
0.5

T
0.5
0.6
0.3
0.5
0.5
0.7
0.5
0.5
0.7
0.7
0.6
0.5
0.5
0.5
0.7
0.6
0.3

V
0.5
0.6
0.5
0.6
0.7
0.5
0.5
0.5
0.6
0.6
0.5
0.5
0.6
0.5
1.1
0.8
0.9
1

W
0.5
0.3
0.3
0.4
0.6
0.4
0.5
0.4
0.3
0.4
0.4
0.7
0.5
0.6
0.4
0.3
0.6
0.4
0.5

Y
0.4
0.5
0.5
0.6
0.5
0.5
0.4
0.6
0.5
0.5
0.4
0.4
0.7
0.5
0.4
0.5
0.9
0.4
0.5
0.5
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Table 4.3. Values of the parameter re for each residue pairs.
A
C
D
E
F
G
H
I
K
L
M
N
P
Q
R
S
T
V
W
Y

A
5.9

C
5
4.3

D
4.9
4.3
4.6

E
4.3
8.1
4.4
4.5

F
4.9
4.5
4.4
4.7
4.6

G
4.5
5.2
5.3
4.3
5
6.1

H
5.8
4.3
5.4
4.9
5.1
5.4
4.8

I
4.9
4.5
4.7
5
5
6
5.9
5.9

K
5.7
5.3
4.4
4.4
4.7
6.1
4.6
6.2
6.1

L
4.5
4.5
6.7
6.2
4.7
6.2
4.8
6.2
6.7
6

M
5.8
4.4
4.5
5.2
4.5
5.8
5
6
6
6
5.1

N
4.4
4.5
4.7
5.2
5
4.8
4.8
6
6.1
4.8
6.2
5.1

P
5.6
4.3
5.4
4.3
4.8
6.1
5.8
6
6.2
6.2
4.6
5.8
6.1

Q
5.1
4.7
5
5
4.5
5.8
6.1
6
5.9
5.2
4.7
6.1
5.5
5

R
5
4.4
5.9
4.9
5.8
4.3
6.1
5.8
6.2
6.2
6.1
4.4
7.1
5
4.3

S
5.5
5.1
5
5
6
6.2
6
5.8
6
6.1
6.1
5
5
4.8
4.3
6.1

T
4.3
4.8
6.1
4.4
5.7
6.1
5.1
4.6
6.1
6
6
5.2
5.4
6.2
5.5
4.8
6.1

V
5
4.6
5
5
6.2
5.2
4.5
5.8
6.2
5.7
5.6
5.4
4.9
5.1
5.9
5.2
5.1
5

W
4.9
4.7
4.3
4.5
5
5.9
4.6
6.1
5.9
5.3
6.1
6.1
6.1
5.1
4.8
5.1
6.1
5
4.9

Y
4.8
4.7
4.8
5
5
5.8
4.5
6
5.9
5.8
4.5
4.9
5
6.2
5
5.1
6
7.4
4.8
6.8
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Table 4.4. The success rates and average Z-scores of different SCM potentials.
Source

RAPDF-SCMa

KBP-SCMa

DFIRE-SCMa

Compact-SCMb

Compact-SCMc

lattice_ssfit

6/8 (3.21)

6/8 (5.11)

8/8 (6.19)

5/8 (1.17)

3/3 (1.52)

lmds

2/10 (1.78)

4/10 (2.59)

3/10 (2.56)

3/10 (1.98)

3/9 (2.04)

fisa

1/4 (2.51)

3/4 (3.99)

3/4 (4.70)

4/4 (3.96)

4/4 (3.96)

fisa_casp3

2/3 (3.70)

3/3 (4.96)

3/3 (6.05)

3/3 (1.49)

3/3 (1.49)

CASP4

19/23 (2.74)

17/23 (3.83)

19/23 (3.15)

15/21 (2.49)

7/10 (1.01)

Rosetta

27/41 (3.55)

29/41 (4.16)

33/41 (4.90)

19/24 (2.54)

19/24 (2.38)

Summary

64.0% (2.92)

69.7% (4.11)

71.9% (4.59)

70.0% (2.27)

73.6% (2.06)

Parameters

7560

5880

8400

630

630

a

(Zhang, Liu et al. 2004)

b

Tested with all decoys

c

Tested with filtered decoys

Numbers in parentheses are average Z-scores
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Table 4.5. The success rate of other energy models
Source

ModPipe- ModPipe- ModPipeForce
DFIREb CompactRosettaa
DOPEa PC2CAa
a
a
a
a
a DFMAC
Pair
model
SCM
A
Surf
Comb

lattice_ssfit

3/3

3/3

3/3

2/3

3/3

3/3

3/3

3/3

2/2

3/3

lmds

6/9

2/9

3/9

2/9

3/9

6/9

6/9

9/9

2/3

3/9

fisa

3/4

1/4

0/4

1/4

0/4

3/4

4/4

4/4

1/1

4/4

fisa_casp3

3/3

0/3

2/3

0/3

2/3

3/3

3/3

1/2

1/2

3/3

Correct

15

6

8

5

8

15

16

17

6

13

Parameters
a

(Mirzaie, Eslahchi et al. 2009)

b

(Makino and Itoh 2008)

>200,000

630
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Table 4.6. The Ranking of native structures for 9 docking decoy sets.
1ugha

2sica

1cgia

1dfja

1ahwb

1bvkb

1dqjb

1mlcb

1wejb

LLSc

1

1

1

4

3

4

4

3

1

DFIRE-SCMd

1

1

1

1

1

1

1

1

2

Compact-SCM

1

61

1

1

1

1

1

1

55

PDB ID

a

Dimers

b

Trimers

c

(Lu, Lu et al. 2003)

d

(Zhang, Liu et al. 2004)
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Figure 4.1. Accuracy of different potential functions. The mathematical expressions and curves were shown for (a) Gaussian’s
function, (b) Lennard-Jones function, and (c) Morse function. (d) In the test of 70 standard multiple decoy sets, four different
functions obtained accuracies of 37%, 31%, 50%, and 70%, respectively.
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5. OVERALL SUMMARY
In this study, the structural basis of caspase-3 substrate specificity was investigated by
crystallographic study and structural modeling. Subsites from S1 to S5 in the caspase-3 substrate
binding groove showed different characteristics for substrate recognition. Specifically, the S1
pocket which is highly positive and stringent for P1 Asp, is formed by Arg64, Arg207, and
Gln161. Our observation is consistent with the previous conclusion that the S1 pocket
exclusively recognizes P1 Asp (Talanian, Quinlan et al. 1997; Thornberry, Rano et al. 1997).
The S2 pocket is surrounded by three aromatic residues, Tyr204, Trp206, and Phe256. This
pocket prefers hydrophobic residues with small side chains, and its size can be adjusted upon the
binding of different P2 residues. The S3 pocket, mainly formed by Arg207, is open at the protein
surface and prefers hydrophilic P3 residues. The S4 pocket can accommodate both polar and
nonpolar residues. Crystal structures showed that Trp206 and Trp214 in the S4 pocket interacted
with P4 Ile or Tyr. Computational modeling suggested that most nonpolar P4 residues, except
Trp, can interact with either Trp206 or Trp214 (Fang, Fu et al. 2009). The S5 pocket, formed by
Phe250 and Phe252, was newly identified by our study. It can interact with P4 Trp and P5
residues with hydrophobic side chains. Binding of P5-containing peptides leads to
conformational changes in the L4 loop via an induced fit mechanism (Fang, Boross et al. 2006).
The comparison of seven caspase-3 crystal structures indicated that most (S2-S5) of the caspase3 substrate binding groove is flexible, and only the S1 pocket is stringent in recognition of amino
acids. The S1-S5 binding sites are interdependent, as different substrate residues at one position
also showed impact on the binding of residues at other positions (Fang, Boross et al. 2006).
Besides the crystallographic analysis, a computational study was performed to develop
novel knowledge-based potential functions for evaluating the quality of protein structural models.

112
Our new potential energy function Compact-SCM was established using Morse’s potential
functions. It achieved a comparable accuracy to the best previous method in the same category.
More importantly, the number of adjustable parameters used by Compact-SCM is 90% fewer
than other residue-level potentials and over 99% fewer than atomic-level potentials. It suggests
that our method is more statistically significant and thus better captures the hidden features of
protein potential energy. In contrast to traditional knowledge-based potentials, our potential
energy functions are defined by differentiable mathematical expressions, which are more
physically meaningful and can be directly applied for molecular mechanics. Thus the CompactSCM is a new type of potential function that combines the advantages of both physics-based
potentials and knowledge-based potentials.
Overall, my research will be helpful for the future design of caspase-based drugs in the
following two aspects. First, the analysis of the substrate binding sites in caspase-3 and
conformations of different residues in the inhibitors provides direct guidance for the design of
the next generation of drug candidates. Second, our new potential functions can be used in the
prediction of protein structures and protein-ligand structures, which is a widely used technique
for screening potential protein inhibitors.
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APPENDICES

I. List of All Caspase Complexes Studied and Publications
Protein

Inhibitor

PDB

Purifi-

Crystalli- Solve

Enzyme

code

cation

zation

Kinetics

Caspase-3

Ac-DEVD-Cho

2H5I

#

#

#

#

Caspase-3

Ac-DMQD-Cho

2H5J

#

#

#

#

Caspase-3

Ac-VDVAD-Cho

2H65

#

#

#

#

Caspase-3

Ac-IEPD-Cho

3GJT

#

#

#

#

Caspase-3

Ac-WEHD-Cho

3GJQ

#

#

#

#

Caspase-3

Ac-YVAD-Cho

3GJS

*

*

*

#

Caspase-3

Boc-D(OMe)-Fmk

3GJR

#

#

#

#

Caspase-3

Ac-LDESD-Cho

3EDQ

*

*

*

#

Caspase-7

Ac-DMQD-Cho

2QL5

*

#

Caspase-7

Ac-DQMD-Cho

2QL9

*

#

Caspase-7

Ac-DNLD-Cho

2QLF

*

#

Caspase-7

Ac-IEPD-Cho

2QL7

*

#

Caspase-7

Ac-ESMD-Cho

2QLB

*

#

Caspase-7

Ac-WEHD-Cho

2QLJ

*

#

Caspase-7

Ac-YVAD-Cho

3IBC

*

#

Caspase-7

Ac-LDESD-Cho

3EDR

*

#

# full contribution *partial contribution N/A not published yet
Related publications are listed below.
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1. Agniswamy J, Fang B, Weber IT. Catalytic restrictions in the active site of human caspase-7
revealed by unliganded and inhibited structures. Apoptosis. 2009 14(10):1135-44.
2. Fang B, Fu G, Agniswamy J, Harrison RW, Weber IT. Caspase-3 binds diverse P4 residues in
peptides as revealed by crystallography and structural modeling. Apoptosis. 2009 May
14(5):741-752.
3. Weber IT, Fang B, Agniswamy J. Caspases: structure-guided design of drugs to control cell
death. Mini Rev Med Chem 2008;8: 1154-1162.
4. Fu G, Chumanevich AA, Agniswamy J, Fang B, Harrison RW, Weber IT. Structural basis for
executioner caspase recognition of P5 position in substrates. Apoptosis 2008;13: 1291-1302.
5. Agniswamy J, Fang B, Weber IT. Plasticity of S2-S4 specificity pockets of executioner
caspase-7 revealed by structural and kinetic analysis. FEBS J. 2007 Aug 14
6. Fang B, Boross PI, Tozser J, Weber IT. Structural and kinetic analysis of caspase-3 reveals
role for s5 binding site in substrate recognition. J Mol Biol. 2006 Jul 14;360(3):654-66.

II. Mutagenesis Study in the S4 Binding Site of Caspase-3
Enzyme kinetic studies have showed that caspase-3 prefers the aspartic acid residue at P4
position on its substrate and any substitution dramatically decrease substrate binding affinity.
Our molecular modeling study in chapter three, however, suggested that the glutamic acid can
bind in the S4 pocket and form hydrogen bonds with F250 and S209. Since Glu and Asp only
differ from one side chain carbon atom, what make caspase-3 stringently prefer Asp at P4? This
question still remains to be a mystery. We observed in several caspase-3 structures that the P4
aspartic acid form water mediated hydrogen bond interactions with some protein residues nearby
the S4 subsite, including D221, W214, and Q217. In order to examine the effect of these indirect
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interactions to the P4 binding, mutagenesis and enzyme kinetic studies were performed. In
addition, crystallization of caspae-3 mutant was also performed.
Three caspase-3 mutants, D221A, W214A, and Q217A were made following the standard
site-directed mutagenesis protocol using PCR. The following protein expression, purification,
and kinetic analysis were performed using the same protocol described in previous chapters.
Three caspase-3 mutants were successfully constructed and expressed. However, the
yield of purified enzyme is low. The enzyme kinetic study indicated that all three caspase-3
mutants have very low catalytic activities on the canonical substrate Ac-DEVD-pNA. Since the
exclusion of one water mediated hydrogen bond should not substantially decrease the catalytic
activity, we suspect that the mutated residues must be important for the correct folding of the
substrate binding pocket. The active site conformation of caspase-3 might be changed by the
mutation leading to the dropped activity. This explains the low yield of protein purification as
caspase-3 needs to be processed to the active form by its own proteolytic activity. However, the
crystallization was unsuccessful, thus structural evidence of our hypothesis is still missing.

